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Abstract:  
 
The emerging importance of social media in business organizations is raising the 
awareness of the decision makers towards this thematic. Platforms such as Facebook, 
Twitter and YouTube are now a part of the businesses communication strategies, leading 
to a dialogue between users/consumers and marketers. In the pharmaceutical industry 
similar communication strategies are being adopted. However, this industry and specially 
its marketing department are subjected to intensive regulations due to the healthcare 
nature of the business, that can suppress a quick adoption of these platforms. Moreover, 
in the pharmaceutical marketing environment, the lack of official and specific regulations 
for social media creates uncertainty, which also turns social media implementation 
process into a difficult path to follow. 
This research has as objective to evaluate the presence of the pharmaceutical 
industry on social media platforms such as Facebook, Twitter and YouTube, and 
characterize the types of digital engagement strategies used. 
To perform this research, a new methodological approach and concept model were 
developed in order to evaluate the top 20 pharmaceutical companies’ presence on the 
selected social media. This new methodology includes a descriptive analysis of each 
social media platform for each pharmaceutical company, followed by a cluster analysis 
with a characterization of each cluster using a crosstabs analysis. 
Findings from this study show that not all pharmaceutical companies are present 
on social media, and some platforms are more used than others. Interestingly the level of 
engagement was not associated with the size of the companies and the digital engagement 
strategies varied between the analysed social media platforms. 
This research provides insights of how pharmaceutical companies are organized 
on social media, and clearly contributes with a framework and methodology for future 
researches in this domain. Also, some of the limitations encountered provide suggestions 
of how to proceed in future studies. 
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Resumo: 
 
Com o aumento da importância dada aos social media pelo mundo empresarial, 
os decisores estão cada vez mais interessados nesta temática. As plataformas online como 
o Facebook, Twitter e YouTube fazem, hoje em dia, parte das estratégias comunicacionais 
das empresas, provocando um diálogo entre os marketers e os utilizadores/consumidores. 
Embora estas estratégias comunicacionais estejam a ser usadas na indústria farmacêutica, 
esta indústria, e especialmente o seu departamento de marketing, encontra-se sob altas 
pressões regulamentares devido à natureza do seu negócio que podem suprimir a adesão 
rápida aos social media. Também devido à falta de regulação oficial e específica dirigida 
para os social media, torna-se difícil, ao nível do marketing farmacêutico, delinear uma 
estratégia comunicacional nesta área. 
Esta investigação tem como objetivo avaliar a presença da indústria farmacêutica 
nos social media, nomeadamente no Facebook, Twitter e YouTube, e ao mesmo tempo 
caracterizar as diferentes estratégias para o engagement digital. 
De forma a concretizar esta investigação foi desenvolvida uma abordagem 
metodológica específica e um modelo concetual que permitiu avaliar a presença nos 
social media selecionados, das principais 20 das empresas farmacêuticas a nível mundial. 
Este trabalho incluiu uma análise descritiva das plataformas usadas por cada empresa 
farmacêutica, bem como uma análise de clusters seguida de uma caracterização de cada 
cluster através de uma análise “crosstabs”. 
Através desta investigação foi possível constatar que nem todas as empresas 
farmacêuticas estão presentes nos social media e que o nível de adoção de algumas 
plataformas difere entre elas. Verificou-se, também, que o nível de engagement parece 
não estar associado à dimensão das empresas e que as estratégias para o engagement 
digital variam entre plataformas. 
Esta investigação tenta fornecer uma visão sobre a atuação das empresas 
farmacêuticas ao nível dos social media e, ao mesmo tempo, contribui com uma 
metodologia e um modelo base para futuras investigações nesta área. Algumas das 
limitações encontradas serão trilhos para investigações a desenvolver no futuro. 
 
Palavras-chave: Marketing Farmacêutico, Facebook, Twitter, YouTube, Engagement
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 CHAPTER 1 – INTRODUCTION 
Companies are concentrating efforts in social media (e.g., Facebook, Twitter and 
YouTube) in order to increase their streams of profit (Kaplan & Haenlein, 2010). 
In the pharmaceutical market, social media is changing habits, allowing bi-
directional conversations between consumers and pharmaceutical companies, and 
through it provides a shift of power from the industry to consumers, transforming them 
into active players (Rollins & Perri, 2013). Bolotaeva and Cata (2011) further states that 
social media can leverage brand presence and awareness while reducing budget 
requirements. 
While social media seems to bring huge advantages for pharmaceutical 
companies, it seems their adherence to these platforms is facing several setbacks. 
According to Rollins and Perri (2013), pharmaceutical companies are experiencing 
ethical and legal issues when trying to adopt these platforms. Studies of Shankar and Li 
(2014) and Aitken, Altmann, and Rosen (2014) provided insights of social media 
presence of pharmaceutical companies in 2011 and 2014, respectively. Like these authors, 
one of the objectives of this research is to assess the current social media presence of 
selected pharmaceutical companies. 
According to Liu and Fraser (2012), the pharmaceutical industry is performing 
poorly in terms of engagement when comparing with other industries. For this reason it 
is important to assess the level of engagement of each company and try to identify if they 
perform identically or if in fact they have distinguished behaviours on the different social 
media platforms, and therefore assess their digital engagement strategies. Also for Aitken, 
Altmann, and Rosen (2014) it seems to exist an association between the size of the 
pharmaceutical companies and their digital engagement performance. In accordance with 
this line of thought, this research tries to provide insights about this subject, through the 
analysis of pharmaceutical companies’ activity on Facebook, Twitter and YouTube.  
In order to develop this research and achieve its proposed objectives, five chapters 
were produced, as clearly demonstrated in Figure 1. 
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Figure 1 – Research structure 
  
The present chapter, provides a short introduction to the research purpose, as well 
as the questions raised by the literature that led to the formulation of the objectives of this 
research. Also in this chapter, it is given a view of the research structure.  
The second chapter presents a compilation of the state of the art of pharmaceutical 
marketing and social media in a single and articulated perspective, through published 
researches and other relevant articles.  
As for the third chapter, it includes an innovative conceptual model as well as the 
theoretical hypothesis raised by the literature, which led to the creation of the research 
framework. Also it is provided all the information about the steps taken in order to achieve 
the objectives of this research.  
With all the data collected, it was necessary to analyse and interpret the raw data, 
leading to the creation of the fourth chapter.  
In the final chapter, all the conclusions of this research are summarized, including 
the limitations that emerged during this research. Also it is provided insights for future 
researches and the major contributions to firm’s management.  
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CHAPTER 2 – LITERATURE REVIEW 
 
2.1. Introduction 
The Cambridge Healthtech Institute (2008) stated that over the last years, 
pharmaceutical companies have had huge success, as never seen before. However, this 
institute states that the growth and profitability of the pharmaceutical industry in the past 
cannot continue in a market highly modified as the pharmaceutical market in XXI 
century. It is clear that pharmaceutical companies’ leaders need to understand the changes 
in this market and identify new strategies in order to have a positive dynamic, leading to 
a successful future and efficient management of challenges (Cambridge Healthtech 
Institute, 2008).  
With the fast growth of online social networking dedicated to healthcare, the 
healthcare systems are being submitted to an enormous increase of complexity (Griffiths 
et al., 2012).  
According to Fox and Jones (2009) cited in Green and Kesselheim (2010), 
Facebook and Twitter, two of the biggest online social networks, possess around 350 
million users worldwide. These authors state that some researches indicate that 60% of 
North Americans use the internet as a first source of healthcare information and also use 
these online platforms to find support in healthcare matters.  
In the meanwhile, pharmaceutical industry has been slow in the adoption of this 
type of platforms (Green & Kesselheim, 2010).  
As stated by Masood, Ibrahim, Hassali and Ahmed (2009), pharmaceutical 
marketing has been trying to acquire new methods along with the evolution of technology 
(e.g., blogs, social networks, etc.) and these new methods are being used independently 
or as a support to traditional marketing.  
Therefore, social networks represent a new way for pharmaceutical companies to 
interact with consumers and physicians (Webb, 2010). However, according to this author, 
the transition to the internet of the communication with the physician and marketing 
campaigns raises several regulatory and legal questions.  
Nevertheless, Webb states that regulatory issues are only one part of the concerns 
of companies that use the internet. Due to the reach of the internet, these companies need 
to manage relationships with customers, since these consumers have at their disposal a 
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wide-ranging platform that gives them a unique power of communication: they are not 
just being receptors of messages; they are being active broadcasters and participants 
(Webb, 2010). 
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2.2. Evolution of pharmaceutical marketing 
The pharmaceutical industry is different from other types of industry (Stremersh 
& Van Dyck, 2009 cited in Ding, Eliashberg & Stremersch, 2014). It’s a science-based 
industry highly regulated when comparing to other industries. Because medicines have a 
massive impact on the quality of life of people, the global system constituted by 
regulators, healthcare providers (e.g., physicians or pharmacists) and payers (e.g., 
government and insurance companies) is architected in order to protect the welfare of 
patients at a tolerable cost (Ding, Eliashberg & Stremersch, 2014). 
According to Ding, Eliashberg and Stremersch (2014), the pharmaceutical 
industry has been growing in a steady way, around 4% to 7% annually and is getting 
quickly to a market value of 1 trillion American dollars, while facing difficult challenges 
in innovation and marketing. These authors declare that a company with a low capability 
for innovation will have a low differentiation potential, leading to lower margins, while 
a company with weak marketing skills will not fully leverage the value that innovation 
can bring, and consequently will have potential losses of billions of dollars which are 
required for their stakeholders and for a constant innovation. Therefore, companies who 
have a robust innovation and marketing skills have been able to manage effectively their 
challenges and will keep generating value for their stakeholders (Ding, Eliashberg & 
Stremersch, 2014). 
As stated by Ding, Eliashberg and Stremersch (2014), society sees two conflicting 
features in medicines. Not only they view them as a normal commodity that satisfies some 
consumer needs, but also as something that people consider as a basic necessity. These 
authors express that pharmaceutical companies must be aware of these two features while 
they capitalize on their innovations. As we can see in Figure 2, this task demands a 
cautious management not only of the relationship between the company with its 3 key 
stakeholders (patient, healthcare provider and payer), but also the relation between these 
stakeholders, all subject to tight regulatory pressures from regulatory bodies (Ding, 
Eliashberg & Stremersch, 2014).  
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Figure 2 – Players and relationships in the pharmaceutical market 
 
 
Source: Adapted from Ding, Eliashberg and Stremersch (2014), p. 6 
 
Also Busfield (2010) provides, through Table 1, his vision of the key players (and 
their characteristics) in the pharmaceutical market.  
 
Table 1 – Key actors and influences on medicine use 
Actor Role Actor’s own expansionary ideas and actions External pressures 
Pharmaceutical 
industry 
Developers, 
producers, promoters 
and sellers 
Desire to increase profits mechanisms: 
(a) Marketing/promotion to physicians and 
public  
(b) Control over science 
(c) Disease mongering 
 
×(a) Cost controls of governments and 
insurance companies 
×(b) Drug licensing and safety 
regulations 
Physicians Prescribers and 
gatekeepers; 
sometimes researchers 
(a) Interventionism 
(b) Imbalances in risk assessment 
(c) Limited knowledge 
(d) Medicalization 
++(a) Industry’s promotion of medicines 
+(b) Patients’ requests 
+(c) Greater risk consciousness 
××(d) Cost controls of governments and 
insurance companies 
The public Potential users (a) Desire to get better 
(b) Belief in the value of medicines 
(c) Active consumers/expert patients 
 
++(a) Industry’s promotion of medicines 
+(b) Growth of consumer-oriented 
culture 
+(c) Government focus on choice and 
the expert patient 
 
 
Governments and 
insurance 
companies 
Set framework of 
health care including 
access to medicines; 
funders of health care; 
responsibilities in 
safety 
(a) Improving access to health care 
(b) Supporting choice 
(c) Value of industry to the economy 
++(a) Industry’s promotion of medicines 
××(b) Growing cost of health care 
provision 
Note:  ++ = strong expansionary pressure; + = weaker expansionary pressure 
           ×× = strong constraint on expansion; × = weaker constraint on expansion 
 
Source: Adapted from Busfield (2010), p. 940 
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According to Rollins and Perri (2013), pharmaceutical marketing has been 
changing radically since the 90s. These authors affirm that before the 90s the promotion 
of pharmaceutical products was focused almost on healthcare professionals. They also 
state that pharmaceutical marketing had a model of direct sales oriented to prescribers 
(e.g., physician) that was associated with a high investment in the promotion of the 
product. Nowadays, diverse stakeholders are involved in the marketing and sales practice. 
Payers and pharmacists are a part of the distribution channel, and can have a major role 
in the decision of the dispensed product to the patient (Rollins & Perri, 2013). Sales 
representatives of pharmaceutical companies do not have the same easy access to the 
physician of the past and their promotional tools are more regulated. In order to change 
this trend, pharmaceutical companies started to explore the power of the internet, through 
websites and mobile technologies, allowing them to spread information to physicians 
(Rollins & Perri, 2013).  
Rollins and Perri (2013) express that the pharmaceutical industry is far behind 
when comparing to other traditional industries that use direct-to-consumer (DTC) 
marketing. For these authors, it is clear that this industry needs to change its marketing 
model based on a push approach into a pull model that is oriented to the consumer (e.g., 
DTC advertising). They also state that nowadays, social media (e.g., social networks) is 
having a crucial role, allowing not only the passage from a one way conversation to a 
dialogue between the consumer and pharmaceutical companies, but also a shift of power 
from the pharmaceutical companies to the consumers. In this way, the consumer becomes 
an active participant in the choice of his treatment and is integrated in the pharmaceutical 
marketing environment (Rollins & Perri, 2013). 
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2.2.1. Different models approaches 
According to Fischer (2014), the pharmaceutical marketing practice is mutating. 
This author states that the major approach of the 90s and begging of 2000 was the increase 
of the sales force, allowing the intensification of the diffusion of scientific information. 
However, Fischer explains that the spending with this approach is decreasing over time 
and nowadays pharmaceutical companies are leaving the commercial model based on the 
sales force, and are adopting, a more complex communication strategy. Through Figure 
3, Fischer gives an explanation of this new strategy that is composed of more channels of 
communication which communicate with other stakeholders (e.g., patients, payers, 
healthcare organizations and professionals), surpassing the almost unique channel based 
on communication with physicians. The spreading of communication channels and 
potential message recipients is being perceived as a major trend in pharmaceutical 
marketing (Fischer, 2014).  
 
Figure 3 – Pharmaceutical spend categories 
 
 
Source: Adapted from Fischer (2014), p. 560 
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Physician-oriented model 
 
The pharmaceutical marketing budget is being largely allocated to communicate 
with physicians (Manchanda & Honka, 2005; Neslin, 2001; Wittink, 2002 cited in 
Fischer, 2014).  According to Fischer (2014), in this communication, pharmaceutical 
companies are using personal selling through detailing1 which is directed to physicians 
that are general practitioners, specialists and hospital physicians. This regulation-
dependent model can include: (1) personal selling with discussion of a limited number of 
products; (2) delivery of some presents and medication samples; (3) payment of meals; 
(4) conference-related issues; (5) financing of medical education and scientific projects; 
(6) publicity in professional journals (Rollins & Perri, 2013; Fischer, 2014).  
Fischer states that methods like medical education and drug-vigilance studies were 
developed to strengthen the relationship with physicians and sometimes certain 
physicians can be provided with financial support from pharmaceutical companies if they 
are open for reporting their observations on patient trial studies associated with a 
promoted medicine. Other channels like direct mailings allow pharmaceutical companies 
to deliver information about treatments or medicines to physicians (Fischer, 2014).  
Fischer (2014) also considers that the traditional communication model is under 
fire from the rise of the internet and other digital media. This author states that the study 
“Taking the Pulse® Europe”, based on physicians behaviour on the internet revealed that 
physicians are using the internet to diversify the reach of their influence (Manhattan 
Research, 2008 cited in Fischer, 2014, p. 559). Fischer refers that the findings in this study 
shows that in the main European countries, 95% of the physicians inquired said that 
internet is useful in their professional practice and for this reason it seems that 
pharmaceutical companies are walking sideways with physicians in this matter through 
the development of electronic strategies.  
According to Masood, Ibrahim, Hassali and Ahmed (2009), online detailing to 
physicians emerged with the evolution of technology, allowing marketers to promote 
products through a new channel.  
1 Detailing is “an educational activity by pharmaceutical manufacturer sales representatives aimed at 
providing details or scientific information on a product’s potential uses, benefits, side/adverse effects” 
(Rollins & Perri, 2013, p. 264). 
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It is clear that a growing number of physicians are networking online, and for that 
reason pharmaceutical companies see as a priority the diffusion of information through 
online networking platforms (Ding, Eliashberg & Stremersch, 2014). 
 
Patient/consumer-oriented model 
 
According to Fischer (2014), there is a part of pharmaceutical marketing that is 
being oriented to patients/consumers, but this direct activity is only accepted in a small 
group of countries like New Zealand and United States of America (USA). However, in 
European Union (EU), pharmaceutical companies can advertise directly to consumers 
when the advertised product is an over-the-counter (OTC) medicine2 (Buckley, 2004).  
Fischer (2014) points that DTC advertising use channels like traditional media 
(e.g. print media, television and radio) and digital media. When DTC advertising is not 
allowed in a country, companies use a below-the-line strategy (e.g. Public Relations 
campaigns associated with diseases and treatments) in order to influence 
patients/consumers. Though, usually in this type of campaign the branded medicine’s 
name is not promoted (Fischer, 2014). Nevertheless, the global reach of online platforms 
poses a challenge in this diversified worldwide setting of regulations (Ding, Eliashberg 
& Stremersch, 2014).  
 
 Model oriented at other stakeholders 
 
According to Fischer (2014), the physicians and patients/consumers are not the 
only stakeholders targeted by pharmaceutical marketing. This author states that to reach 
this new audience, pharmaceutical companies developed communication strategies that 
include detailing to pharmacists, practice nurses and managed care providers. Fischer also 
affirms that the influence of these stakeholders as gatekeepers changes according to the 
type of medicines and healthcare structure. He exemplifies that in the healthcare business 
associated with diabetes, a major part of the budget is allocated to sales representatives 
in order to reach practice nurses and pharmacists since these healthcare professionals 
2 According to Lessenger and Feinberg (2008), Collins and MacAllister explained that “OTC medications 
are pharmaceuticals that do not require a prescription and are sold on the shelves of markets, stores, and 
pharmacies” (p. 45) 
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usually recommend devices that measure the blood glucose to people who suffer from 
this disease. Also pharmaceutical companies allocate a part of their budget into corporate 
public relations (Fischer, 2014).  
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2.2.2. Restrictions, limitations and particularities  
The pharmaceutical industry is facing continuous pressures and is being obliged 
to deal with several external factors (e.g. regulatory environment) that are highly 
complex, because each situation depends on its geographic location and local legislation. 
(Ding, Eliashberg & Stremersch, 2014; Desiraju & Tran, 2014). For pharmaceutical 
marketers it is important not only to adapt to a unique external environment but also 
differentiate the ways that different medicines categories are commercialized:  (1) OTC 
medicines vs. prescription medicines; (2) branded medicines vs. generic medicines3 
(Rollins & Perri, 2013). 
 
Regulation 
 
Regulation is without any doubt a factor that distinguishes the pharmaceutical 
industry from other types of industries (Desiraju & Tran, 2014). Regulatory activities are 
present in several pharmaceutical phases like the approval of new medicines, medicine 
surveillance, and production and promotion to physicians and consumers (Ding, 
Eliashberg & Stremersch, 2014). The approval of medicine commercialization requires 
normally a guarantee of safety and efficacy of the product and it is supervised by the Food 
and Drug Administration (FDA) in the USA, by the European Medicines Agency in the 
EU (even though individual country members have their own regulatory bodies) and in 
Japan by the Ministry of Health and Welfare (Morton & Kyle, 2011). 
According to Desiraju and Tran (2014), the regulation of marketing practices is 
not uniform, existing several differences between different areas of the world and between 
pharmaceutical marketing segments. For example, since 2006, in the physician-
pharmaceutical company relationship inside USA territory, it is not possible to 
communicate off-label medication uses4 to a physician, but the physician does not have 
restrictions in using these off-label uses for any situation that he thinks the drug will work 
(Ding, Eliashberg & Stremersch, 2014; Patsy & Ray, 2008). In other areas of the world, 
3 “The term generic refers to the practice of using the International Non-proprietary Name (INN) for the 
chemical, in contrast to a “branded” drug that is marketed with a shorter, trademarked name. For example, 
atorvastatin is the INN corresponding to Pfizer’s Lipitor” (Morton & Kyle, 2011, p. 766). 
4 Turner explained that “off-label prescribing is the prescription of a registered medicine for a use that is 
not included in the product information (Gazarian et al., 2006, p. 544). 
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detailing practices are restricted as well as the medication samples given to physicians 
(Ding, Eliashberg & Stremersch, 2014).  
In accordance with Desiraju and Tran (2014), DTC advertising regulation differs 
between countries or regions. These authors exemplify that while in the USA the DTC 
advertising of prescription medicines is authorised, in the EU and Canada there are 
restrictions for its use.  
To Liu and Gupta (2014), there have been some developments regarding DTC 
advertising in the EU but they did not have a happy ending due to the rejection of 
European Commission propositions by the European Parliament. However, the European 
Commission along with other industries that have interests related with medicines are 
pressuring continuously the adoption of DTC advertising practices (Liu & Gupta, 2014).  
In Canada, as DTC advertising is forbidden, pharmaceutical companies are using 
two types of advertising that are allowed by regulatory institutions. The first type is 
associated with diseases like “help-seeking” advertisements, where non-branded 
communications not only appeal to consumers to seek their physician but also increase 
the awareness of a certain illness, while the second type is “reminder” advertisement that 
is a branded communication but there is not any type of information about the use of the 
medicine (Mintzes, 2006 cited in Liu & Gupta, 2014, p. 635).  
On the other hand, with the World Wide Web, several concerns arise since  online 
advertising can reach places where DTC publicity is not allowed. (Liu & Gupta, 2014). 
As an example, in the GlaxoSmithKline blog and AstraZeneca Facebook page, the 
information is directed only to USA population, but users from all over the globe can 
access this information, surpassing any possible control (Liang & Mackey, 2011a,b cited 
in Liu & Gupta, 2014, p.635). 
In terms of price regulation, there are also differences between nations (Desiraju 
& Tran, 2014). Ding, Eliashberg and Stremersch (2014) highlight that price regulation 
could be through direct price impositions from governments, through price comparison 
between specific countries or through pricing established by comparison of medicines 
with an identical therapeutic category. These authors also state that in some situations, 
governments can limit the global amount of revenues of pharmaceutical companies. 
According to Desiraju and Tran (2014), countries like France, Italy and Japan control 
directly prices while countries like Germany, Netherlands and New Zealand manipulate 
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reimbursements through price orientations, leading to changes in the amount that 
consumers have to pay (Desiraju & Tran, 2014). 
 
OTC medicines versus prescription medicines 
 
For Rollins and Perri (2013), because prescription medicines and OTC medicines 
are used in similar situations, one can think that these products can be commercialized 
equally in terms of marketing communications and strategies, but even though the 
messages could be similar, the receptor of these communications is different for each 
case. These authors state that in the case of prescription medicines, pharmaceutical 
marketers target physicians, pharmacies, wholesalers and payers. All of these 
stakeholders influence which medicine is dispensed to the final consumer.  
Regarding OTC medicines, Rollins and Perri express that physicians and payers 
are not the main focus of OTC marketers. Albeit physicians have knowledge about this 
type of products, they are less empowered in its recommendation, leading to less medical 
communication from pharmaceutical companies. For these authors, the major target of 
OTC products is consumers because they have the decision power in their hands. Rollin 
and Perri affirm that since intermediary agents seem to be absent in the OTC market, this 
market acts as it was a traditional consumer goods market. However, OTC marketers 
target other stakeholders such as pharmacists because not only they are of easy access in 
community pharmacies and mass merchandisers, but also they can influence the decision-
making process of consumers (Rollins & Perri, 2013). 
 
Branded medicines versus generic medicines 
 
According to Garattini and Tediosi (2000), a generic medicine is a trustworthy 
replica of a branded medicine which has its patent expired and is commercialized with 
the active principle’s name of the patented medicine. With the rise of generic medicines, 
pharmaceutical companies stopped with the same nerve-racking approval procedures 
necessary for biosimilar branded medicines, allowing them to save money, time and 
diminish process risk (Rollins & Perri, 2013; Desiraju & Tran, 2014).  
To Rollins and Perri (2013), the key target of pharmaceutical companies of 
branded medicines is the physician while consumers and payers are vital targets for the 
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development of brand loyalty and the maintenance of a favoured status in a formulary5. 
These authors state that generic medicines are similar to commodities in the eyes of the 
pharmaceutical industry, and therefore the marketing mix is focused on price. They also 
affirm that the key target audience of generic medicines is different from the target 
audience of branded medicines. Even though physicians choose the medication for their 
patients, pharmacies are the last intervenient in the supply chain of medicines to patients 
and for this reason they can pick the companies that supply their stock, making them the 
ultimate targets for pharmaceutical marketers of generic medicines (Rollins & Perri, 
2013). However, according to Ding, Eliashberg and Stremersch (2014), both physicians 
and pharmacies can receive financial support from payers in order to encourage the use 
of generic medicines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 According to Rollins and Perri (2013), “a prescription drug formulary, sometimes referred to as a preferred 
drug list, is a complete listing of medications that have been approved for use within a prescription drug 
plan” (pp. 90-91)  
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2.3. Relationship between pharmaceutical industry and its major stakeholders 
Dogramatzis (2001) stated that “a pharmaceutical company’s stakeholder is any 
person or group of persons with which the company has, or wants to develop, a 
relationship” (p. 27). Thus, all pharmaceutical marketers must be aware of the singularity 
of each stakeholder in order to interpret correctly the unique needs of each one of them 
(Dogramatzis, 2001). 
According to this author, there are two types of pharmaceutical company’s 
stakeholders: (i) internal and (ii) external. Internal stakeholders are all company’s 
workers, while external stakeholders result from a combination of different interested 
parties.  
According to Kotler and Clark (1987) cited in Dogramatzis (2001), the external 
stakeholders are divided in three categories: (1) “inputting stakeholders”; (2) “mediators”; 
(3) “consumers".  
Dogramatzis (2001) clarifies that “inputting stakeholders include suppliers, 
regulators, and politicians, because they play a significant influencing role in the 
company’s success”, while the “mediators include prescribers, university professors, and 
other healthcare professionals who stand between the company and its final customers, 
the patients” and the “consumers include not only patients and their families or advocacy 
groups, but the media, general public, and the competitors, too” (pp. 28-29).  
Dogramatzis (2001) gives, in Table 2, his view about the different external 
stakeholders of the pharmaceutical industry, as well as some of their needs and concerns. 
 
Table 2 – Major pharmaceutical industry stakeholders’ characteristics 
Who they are? 
Patients Prescribers Hospitals Influencers Financers Regulators 
- Patient 
- Patient 
advocates 
- Patient families 
- Physicians 
- Non-specialist/ 
specialist 
- Hospitals 
(State, Private, 
Military) 
- Clinics 
- Health 
maintenance 
organisations 
- Ambulatory 
care 
- Nursing homes 
- Opinion leaders 
- Pharmacists 
- Wholesalers 
- Nurses 
- Social workers 
- Consultants 
- Suppliers 
- Reimbursement funds 
- Insurance companies 
- Employers 
- Managed care 
organizations 
- Ministry of Health 
- Registration 
Authority 
- Pricing Authority 
- Patent Office 
- Drug Organization 
- Ethics Committees 
- Formulary 
Committees 
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(Table 2 continued) 
Who they are? 
Patients Prescribers Hospitals Influencers Financers Regulators 
Needs 
- Best possible 
health care 
- Lowest cost 
- Information 
- Choice 
- Privacy 
- Humane 
treatment 
- Efficacy  
- Safety 
- Pursue medical 
rationale 
- Efficacy 
- Safety 
- Tolerability 
- Quality of life 
- Credibility 
- Practice expansion  
- Information 
- Increase 
clientele 
- Increase market 
share 
- Contain costs 
- Opinion leaders need 
professional recognition 
and advancement 
- Healthcare professionals 
need access to choice 
- Pharmacists need 
information and 
protection of profit 
margin 
- Protect patient 
benefit  
- Contain costs 
- Preserve public 
health 
- Provide coverage 
- Ensure efficacy and 
safety 
- Ensure fair pricing 
Issues 
- Prescription vs. 
OTC 
- Compliance 
- Up-to-date 
information 
- Discounts 
- Long payment 
terms 
   
 
Source: Adapted from Dogramatzis (2001), p. 30 
 
The table above shows that each stakeholder presents distinguished needs, 
requiring specific approaches which must be designed taking into consideration 
stakeholders’ main issues and characteristics. 
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2.3.1. Prescribers 
According to Amelung (2013), the gatekeeping process usually begins with an 
appointment with the physician. This author states that usually the general practitioner is 
responsible for the gatekeeping process, but there are situations that a specialist physician 
could perform this function. In this model, the gatekeeper is responsible for the 
management of the treatment process because he will choose what will be the next step 
in the treatment. Amelung provides, through Figure 4, an exemplification of this 
gatekeeping network. 
 
Figure 4 – Gatekeeping system 
 
 
Source: Adapted from Amelung (2013), p. 150 
 
According to Dogramatzis (2001), the prescribers are the main healthcare 
providers with whom pharmaceutical marketing establishes direct interactions. This 
author states that these healthcare professionals try to be up-to-date in terms of scientific 
knowledge associated with their profession, they usually keep their patients’ loyalty when 
working in a private setting and use a cost-benefit approach when associated with a 
managed care organization. Dogramatzis also affirm that during the promotion of 
different medicines, pharmaceutical companies usually interact with a diverse type of 
physicians. This diversity creates a hierarchical pyramid of influence (see Figure 5) where 
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the youngest and inexperienced physicians that are at the bottom of this pyramid seek the 
support of more experienced medical professionals that reside on the top (Dogramatzis, 
2001). 
 
Figure 5 – The pyramid of influence 
 
 
Source: Adapted from Dogramatzis (2001), p. 32 
 
In Figure 5, it is possible to verify that the influencing process begins with opinion 
leaders6 and finalizes with general practitioners through a communication cascade 
scheme, and therefore pharmaceutical marketers must follow this process when they want 
to generate awareness of a new medicine in the healthcare universe (Dogramatzis, 2001). 
According to Dogramatzis (2001), the prescribing decision-making process is 
based on two consecutive steps: (1) choice of a therapeutic category for a specific illness; 
(2) choice of a brand. It is important for pharmaceutical marketers to be aware of the 
stages and influence elements in the prescription process because this knowledge can be 
important for the success of the marketing strategy (Dogramatzis, 2001).  
6 According to Dogramatzis (2001), “opinion leaders may not be active prescribers, holding, instead, 
academic, administrative, or even political positions that keep them away from everyday medical practice” 
(p. 33). 
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Although prescribing role is mostly performed by physicians, in some countries 
like the United Kingdom, nurses and pharmacists can also have this responsibility (with 
limitations) (Latter, et al., 2012). 
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2.3.2. Influencers 
There is a set of individuals who have the power to affect purchase decisions of 
others. This happens because of their real or perceived knowledge, authority, position, or 
relationship. For these reasons they are considered as influencers, and can assume 
different alias. 
 
Opinion leaders 
 
According to Buckwell (2008), opinion leaders use their influencing skills to 
educate other medical professionals. Due to their position in the top of the communication 
cascade of influence (see Figure 5), it is important for pharmaceutical companies not only 
to reach these opinion leaders in the early stages of development of new medicines but 
also provide all the important information, increasing the chances of them becoming 
propagandist of the new product attributes (Dogramatzis, 2001). For this reason, opinion 
leaders are usually present in pre-marketing activities or in consultative councils 
(Dogramatzis, 2001; Rollins & Perri, 2013).  
Buckwell (2008) states that with the rise of social networking anyone can express 
their opinion, so it is important for pharmaceutical companies that have new medicines 
in the pipeline to support key opinion leaders’ influence potential and help increase the 
awareness of their messages. However, it is crucial for a successful relationship that when 
pharmaceutical marketers engage opinion leaders, they use a soft and courteous approach 
and not a hostile one (Dogramatzis, 2001).  
 
Wholesalers 
 
According to Rollins & Perri (2013), the wholesalers are a crucial player in the 
pharmaceutical supply chain and marketing. As they possess a significant number of 
customers, it is important for pharmaceutical marketers to be aware and to respond to 
wholesalers’ needs/requests. These authors state that these marketers must not only 
practice a generous pricing and payment policy towards wholesalers but also have a 
production plan that meets the needs of both wholesalers and pharmacies. As 
compensation, wholesalers can provide priceless information to pharmaceutical 
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companies regarding market share, volume and they also can alert for any logistical 
problem that could be present (Rollins & Perri, 2013). 
 
Pharmacists 
 
According to Chiarello (2013), in today’s pharmacy, pharmacists possess 
university studies in pharmaceutical sciences, allowing them not only to become 
specialists of medicines in the healthcare environment but also experience issues that 
physicians face when dealing with patients. This author states that pharmacists are 
secondary gatekeepers, responsible for later stages of health care, while physicians 
perform the gatekeeping role at the beginning of the health care provision.  
According to Dogramatzis (2001), pharmacists are being seen as crucial players 
in a managed care environment. He further states that, in order to reduce costs, 
pharmacists are more empowered regarding the possibility of substituting medicines. To 
put into practice this increase of empowerment, a pharmacist or a pharmacy benefit 
manager relies on formularies of medicines for the decision-making of which 
bioequivalent medicine (usually a generic medicine) will be dispensed (Dogramatzis, 
2001).  
For Morton and Kyle (2011), some parts of the USA and other developed 
countries promote the use of generic medicines by forcing pharmacists to dispense 
generics (if existing). However, these authors state that there are situations where the 
dispensing of generics is not imposed by authorities, existing only a provision of 
incentives for it. This provision of incentives varies between countries, because of the 
different legal and regulation environments among them. In some countries like Germany 
and the Netherlands, the power of choice of the pharmacist is limited because the 
authorities choose the supplier with the least expensive generic medicine to be responsible 
for providing all the market (Morton & Kyle, 2011). 
According to Drogamatzis (2001), there are differences between hospital 
pharmacists and community pharmacists concerning their needs and wishes.  This author 
states that pharmaceutical companies need to be aware of them because in some situations 
big packages can occupy too much storage space or products with strict conservation 
needs require special storage conditions. Also it is important for pharmaceutical 
marketers to provide pharmacies with informational material for patients along with 
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promotional material (e.g. in-store displays) and publicity campaigns that will attract 
customers, fulfilling in this way the needs of pharmacists (Dogramatzis, 2001). 
 
Other healthcare professionals 
 
In 2001, Dogramatzis advocated that healthcare professionals that are not 
pharmacists and physicians are an essential piece of the healthcare system. He states that 
they have an important active role in the patient treatment, assisting the physician in his 
function. This author also states that healthcare providers such as nurses and 
physiotherapists are sometimes more present in chronic patient treatment than physicians 
and they also can explain medicines’ side-effects and emphasise the importance of 
therapeutic compliance. Dogramatizis affirms that nurses that are following chronic 
patients in a healthcare facility can have the power of choosing the medicines brand (when 
physicians choose only the active principle). Due to the relevance of these healthcare 
professionals in some specific settings, it is important for pharmaceutical companies to 
provide them with information about products and diseases (Dogramatzis, 2001). 
 
Hospital administrators 
 
Hospital administrators are habitually responsible for the hospital budget 
dedicated to medicines, and they can perform their role as customers or influencers in the 
pharmaceutical environment (Dogramatzis, 2001). According to Smith (1991), 
pharmaceutical companies have a new gatekeeper in their environment. This author states 
that hospital administrators have distinguished motivations, experiences and studies when 
comparing with some healthcare professionals. In this new gatekeeping process, there is 
a major control of the access to some parts of the market through a formulary or buying 
orders (Smith, 1991). 
For Smith (1991), pharmaceutical marketers must develop messages that are in 
harmony with the needs (e.g. product and information needs) of hospital administrators, 
in order to increase their success. This author affirms that pharmaceutical companies are 
acknowledging the major role of hospital administrators in the process of medicines 
selection and purchase. One of these companies is Stuard Pharmaceuticals, that used a 
professional journal named “Hospitals” (aimed at hospital management), to promote the 
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higher benefits of the branded medicine “Cefotan” when comparing to cefoxitin and other 
antibiotics (Smith, 1991). 
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2.3.3. Regulators 
Dogramatzis (2001) refers that the pharmaceutical industry is clearly the industry 
most regulated by governments.  This author state that in this industry “there are multiple 
regulatory controls and levels, starting with the institutional to the local, national, 
international, or even global level” (p. 34).   
For example, in the USA, the population requires a prescription from a licensed 
prescriber (e.g. physician) in order to have access to the majority of medicines (Carpenter, 
2010). This author states that the medicines used in the prescription must be previously 
approved by the FDA. In this approval process, the FDA must evaluate the safety and 
effectiveness of medicines in order to see if they are fit for commercialization, making 
this government agency a gatekeeper of the pharmaceutical market. According to 
Carpenter (2010), this gatekeeper role is associated with seven powers: (1) “power to 
define medical success and shape scientific careers”; (2) “power to limit advertising and 
product claims”; (3) “power to govern drug manufacturing”; (4) “power to enable drug 
firms to generate vast riches”; (5) “power to chase...[drug] firms from the marketplace”; 
(6) “power to sculpt medical and scientific concepts; (7) “power to influence the lives and 
deaths of citizens” (p. 1). This regulation has two faces because it can unleash positive or 
negative consequences for pharmaceutical companies (Dogramatzis, 2001). This author 
specifies, in Table 3, the different types of governments’ influence over the 
pharmaceutical industry. 
 
Table 3 – Aspects of Government influence on the pharmaceutical industry 
Funding Regulating Promoting Rewarding 
-  Research & Development 
grants 
- Social security 
- Facility creation 
- Patent protection 
- Registration 
- Reimbursement 
- Pricing 
- Influence on other governments 
- Local industry incentives 
- Substitution legislation 
- Disease diagnosis campaigns 
- Manufacturing 
- Marketing 
- Prescribing decision 
- Trade barriers 
- Innovation awards 
- Export awards 
- Quality awards 
- Orphan drug exclusivity 
 
Source: Adapted from Dogramatzis (2001), p. 35 
 
Adding to this Dogramatzis (2001) suggested that the major problems existing in 
the pharmaceutical industry-government regulation relationship are in the “collaboration, 
compliance, harmonization, negotiation and lobbying” (p. 34). This author states that if 
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the pharmaceutical industry reacts aggressively to regulation, it can create an unfriendly 
environment with regulators that could not be positive for pharmaceutical companies.  
Nowadays, pharmaceutical companies have a Regulatory Affairs department, 
where personnel with scientific background establish specific interactions with regulators 
(Gopinath, Bhadauria, Gunjan & Insha, 2012; Rollins & Perri, 2013).   
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2.3.4. Financers 
Pharmaceutical marketers need to be aware of the medicines financing structure 
in each market when choosing the prices of their products because this financing system 
varies between geographical locations (Dogramatzis, 2001; Morton & Kyle, 2011). 
Dogramatzis (2001) exemplifies, in Figure 6, the most common ways of financing 
medicines.  
 
Figure 6 – Medicines financing methods in different healthcare systems 
 
 
Source: Adapted from Dogramatzis (2001), p. 238 
 
This author states that these methods “are broadly based on long-term financing 
scheme (insurance, social security, and so on) or a fee-for-service consumer copayment” 
(p. 237). Because these methods can influence the consumption of medicines, it is 
important to have them into account when establishing the marketing strategy 
(Dogramatzis, 2001). 
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2.3.5. Consumers 
There are two types of consumers that need to be acknowledged: individuals who 
buy products for personal use and not for manufacture or resale and organizations who 
buy products to incorporate in their delivery system. 
 
Patients 
 
The rise of television advertising and accessibility to information (particular on 
the internet), led to a healthcare model where patients and physicians participate in the 
decision-making process (Rollins & Perri, 2013). Because physicians are not the only 
source of information about treatments, empowered patients (due to the acquisition of 
information from various sources), decide together with the physician what will be the 
best treatment option (Rollins & Perri, 2013). These authors state that with this paradigm 
shift, patients not only have become a main focus of pharmaceutical companies but also 
are demanding the fulfilment of their healthcare and information needs. 
According to Dogramatzis (2001), there are several forms of patient involvement 
and decision-making steps that are related with purchase of medicines: (1) consumer is 
driven by “inertia” when buying OTC medicines (involvement is low and decision-
making a is repetitive process); (2) consumer is driven by “brand loyalty”, for example, 
in chronic situations like asthma (involvement is high and decision-making is a repetitive 
process); (3) consumer seeks different physicians for opinions and pharmaceutical 
solutions (involvement is low and decision-making level is high); (4) consumer that 
requires multiple consultations and diagnostic testing, multi-level intake of medicines and 
lifestyle modifications will have high decision-making and involvement levels. 
Therapeutic non-compliance is a major worldwide subject of discussion. 
(Dogramatzis, 2001; Ilyuk, Irmak, Kramer & Block, 2014). For Ilyuk, Irmak, Kramer and 
Block (2014), the World Health Organization revealed that only nearly 50% of the 
patients in the world follow their medicines prescription correctly. These authors state 
that this problem can result in negative consequences not only for consumers (increase of 
health care risk) but also for pharmaceutical companies. Therapeutic non-compliance is 
facing strong opposition from healthcare providers and pharmaceutical industry because 
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they are using techniques such as the ones included in “disease management initiatives” 
(e.g. treatment guidelines, prevention strategies, etc.) (Dogramatzis, 2001).  
 
Table 4 – Needs or wishes of pharmaceutical industry and patients’ organisations 
 A patients’ organisation needs help with… A pharmaceutical company would like patients to help with… 
[S] – Project funding: surveys of members and of services 
available for them  
[S] [M] – Information about treatments and diagnosis; 
production of information materials 
[M] – Lobbying for resources to help people with the disease 
or problem 
[M] [L] – Business know-how (fundraising, publicising itself, 
growing big) 
[L] – Core funding 
[S] [M] – Market expansion: Use of its drugs by all who might benefit; more 
efficient and prompt diagnosis of the problem the drug is intended for 
[S] [M] – First line use of its products (rather than competing ones) 
[M] – Lobbying against restrictive government or health service policies and 
regulations  
[L] – Being seen as a caring and socially responsible business 
Note: [C]: Short term [M]: Medium term [L]: Long term 
 
Source: Adapted from Herxheimer (2003), p. 1208 
 
Through Table 4, it is possible to verify that patient’s organizations can also 
establish relationships with the pharmaceutical industry (Herxheimer, 2003). 
 
Organizational buyers 
 
According to Dogramatzis (2001), although organizational buyers of medicines 
bear a resemblance to unitary customers, they also possess unique features that need to 
be carefully managed by the pharmaceutical industry. This author states that these 
organizational buyers are “composed of physicians and nurses, hospital pharmacy 
directors, formulary specialists, pharmacy benefit managers, financial administrators, and 
others who usually work in teams assigned to compare, evaluate, and purchase large 
pharmaceutical orders from manufacturers” (p. 37). Individual members of these groups 
can influence, take decisions, perform the gatekeeping process or even be simple users, 
while the whole unit is considered as a “buying center” (Dogramatzis, 2001). 
Also for Dogramatzis (2001), the decision-making process of organizational 
buyers needs to be well scrutinised by pharmaceutical marketers in order to develop a 
strategy that can provide success to pharmaceutical companies. Dogramatzis affirm that 
this strategy must be reformed according to each institution’s needs and also must be 
flexible in order to adapt to changing scenarios.  
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2.4. Pharmaceutical marketing and the social media 
The subject of social media is a high priority of discussion in the business world 
(Kaplan & Haenlein, 2010). These authors state that people responsible for taking 
decisions in companies and also consultants are trying to find ways to increase 
companies’ profitability through social media (e.g. Wikipedia, YouTube, Facebook and 
Twitter). 
According to Aghaei, Nematbakhsh and Farsani (2012), before social media, the 
internet already allowed a limited user interaction. These authors state that the Web 1.0 
(first web generation) is considered to be the “read-only web”. This web provided users 
the possibility of establishing limited interactions and releasing content, but with it users 
could only search and read information (Aghaei, Nematbakhsh & Farsani, 2012). For 
Rollins and Perri (2013), in the middle of the 90s, the increasing people’s awareness of 
the internet provided a new way for them to control the information received. These 
authors state that with the Web 1.0 people started to have access to the content of 
countless diverse websites, as an alternative to the controlled information available, for 
example, in television transmissions and books. Several of these websites appear to be 
like simple brochures, whereas electronic commerce websites were similar to catalogues 
(Rollins & Perri, 2013). 
The Web 2.0 is considered to be the “read-write web” (Aghaei, Nematbakhsh & 
Farsani, 2012; Rollins & Perri, 2013). As said by Aghaei, Nematbakhsh and Farsani 
(2012), the technologies associated with the Web 2.0 permitted the creation of groups of 
people who shared the same interest for social interactions. These authors state that with 
this Web, the online interaction was based on a two-away communication. According to 
Rollins and Perri (2013), in the rise of the Web 2.0, the most relevant information was 
not coming from several media channels but from online users. These authors suggested 
that simultaneously with the rise of the Web 2.0, social networks prototypes started to 
appear, providing new ways for facilitating interactions between people. These prototypes 
converted, with time, into modern social media platforms (e.g. Twitter and Facebook) 
(Rollins & Perri, 2013) 
Kotler and Keller (2011) considered that “social media are a means for consumers 
to share text, images, audio, and video information with each other and with companies 
and vice versa, encouraging brand engagement at a deeper and broader level than before” 
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(p. 291). Likewise, Kietzmann, Hermkens, McCarthy and Silvestre (2011) advocated that 
these social media which are composed of seven functional blocks (see Figure 7) can, 
through mobile and web-based technologies, allow interaction between users. In addition 
to the previous technologies, social media can also employ cloud based technologies 
(Khan, 2012).  
 
Figure 7 – The “honeycomb” of social media 
 
 
Source: Adapted from Kietzmann, Hermkens, McCarthy and Silvestre (2011), p. 243 
 
To Kotler and Keller (2011), social media can provide marketers with the 
possibility of being present on the web, reinforcing their communication strategy. These 
authors state that the most important social media platforms are: (1) forums and online 
communities; (2) social networks; (3) blogs. 
According to Kaplan and Haenlein (2010), social networks sites are applications 
that allow users to interact through online profiles. According to Shankar and Li (2014), 
in 2010, the social networks were adopted by 96% of the Generation Y7 (Shankar & Li, 
7This generation describes the generational cohort after the Generation X. There is not an exact period for 
Generation Y, but researchers believe it is between the beginning of the 80s and the early 2000s. This 
generation uses actively social media platforms for different purposes (Millennials, 2014; Bolton et al., 
2013). 
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2014). For Kotler and Keller (2011), the business-to-consumer and business-to-business 
communication can be leveraged through social networks (e.g. Facebook, Twitter and 
LinkedIn). These authors affirm that marketers are still trying to understand what will be 
the best approach to social networks and their users. They also state that it is difficult to 
capture the attention of users and persuade them because social networks are viewed as 
non-commercial platforms (users want mostly to interact with other users). Moreover, 
Kotler and Keller complement the previous idea saying that the presence of advertising 
content in social network platforms could be viewed by users as inappropriate or 
offensive. Facebook presence has become a must for numerous companies and Twitter 
can enhance businesses (even for small companies) (Kotler & Keller, 2011). Bolotaeva 
and Cata (2011) explain that social networks can leverage brand presence, brand 
awareness and also they can reduce advertisement costs (especially important in fragile 
economic situations).  However, it is important for companies to be aware of ethic matters 
(e.g. user privacy; spamming and publicity policies; data mining and legal concerns) 
(Bolotaeva & Cata, 2011).  
According to Griffiths et al. (2012), social networks allow the exchange of 
healthcare information associated with symptoms, possible diagnosis and treatments, 
adverse effects experienced, medical evidence, as well as opinions about their 
experiences with healthcare providers. These authors affirm that in the health care system, 
there are two sides, namely the patients-side and providers-side that connect with each 
other through common platforms (see Figure 8). In the providers-side there are medical 
technology companies, pharmaceutical companies, healthcare professionals, managers 
and professional groups that control patient data, and through it they can influence the 
shape of health care systems. In the patients-side lays the demand-side, where each single 
patient acquires information from providers and can find support and advices in their 
social circle. Griffiths and colleagues state that in order to establish a connection between 
the two sides, platforms such as physician-patient appointments, health services provided 
by hospitals and communities, organizations functioning as funding channels (e.g. 
Medicare) and other types of interactions between equipment/treatment providers and 
patients, must exist. They also emphasize that online social networking can also be a form 
of interaction between the two sides. These platforms can be important in the gatekeeping 
and mediation process and can act as a vehicle for information (Griffiths et al, 2012).  
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Figure 8 – The health care system as a two-sided network  
 
 
Source: Adapted from Griffiths et al. (2012), p. 2235 
 
According to Shankar and Li (2014), the rise of e-communications through social 
media is changing healthcare and pharmaceutical industry. Liu and Fraser (2012) stated 
that the empowerment among patients and providers is increasing and social media is 
allowing greater control to their users. These empowered audiences will establish 
connections with the pharmaceutical industry through social media if pharmaceutical 
companies are trustworthy through their eyes and have something positive to offer (Liu 
& Fraser, 2012). According to Rollins and Perri (2013), social media platforms provide 
wonderful opportunities for pharmaceutical marketers interact with their customers and 
acquire knowledge of their markets. In order to pharmaceutical marketers effectively 
manage these platforms, they need to understand how to listen to customers’ voices and 
approach these customers; they need to create optimized messages for each scenario and 
possess a great ability to adapt to regulatory and technological settings that are in constant 
mutation (Rollins & Perri, 2013). Liu and Fraser (2012) suggested that pharmaceutical 
companies can gather data through social media platforms that are important for brand 
monitoring and can also obtain critical information about consumers. For them, these two 
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resources enable pharmaceutical companies to develop innovative marketing strategies 
and services that could increase brand awareness, customer loyalty, improve patient 
compliance, as well as respond promptly to information requests from patients and 
physicians. However, the data such as the user-generated content created and provided 
by patients and physicians needs to be treated in a secured environment, according to 
regulations (Liu & Fraser, 2012). 
 Nevertheless, several pharmaceutical companies are ignoring this social media 
adherence trend due to ethical and legal issues that surround these platforms (Rollins & 
Perri, 2013). Aitken, Altmann and Rosen (2014) noticed that the global reach of social 
media poses several problems to pharmaceutical companies because of the regulatory 
discrepancies between regions and countries (see Table 5).  
 
Table 5 – Regulation differences of key regions/countries 
Country/Region Regulatory bodies Key documents Additional comments 
EU 
- International Federation of 
Pharmaceutical Manufacturers 
and Associations (IFPMA): 
self-regulating 
- Regulatory document rejected 
in June 2009 
- United Kingdom - ABPI’s 
Code of Practice for the 
Promotion of Prescription-Only 
Medicines (the “ABPI Code”) 
- While little regulation exists companies are self-
regulating: digital marketing strategies are underway 
but investment is small and initiatives limited in scope 
- Regulators fear DTC information and escalating 
pharma costs due to increased patient advocacy for 
drugs. 
- The European Federation of Pharmaceutical 
Industries and Associations (EFPIA) is attempting to 
push for self-regulation 
 
USA 
- Food and Drug 
Administration (FDA) 
 
- The Office of Prescription 
Drug Promotion (OPDP) 
- Guidance for Industry: 
Responding to Unsolicited 
Requests for Off-Label 
Information About Prescription 
Drugs and Medical Devices, 
Dec 2011 
- Update expected by July 2014 
at the latest - “The development 
and issuance of guidance for 
social media is among the 
highest of FDA’s priorities” 
- The existing guidance for the pharmaceutical 
industry mostly governs the topic of off-label usage. 
Other regulations must be extrapolated from precedent 
- The “One Click Rule” is inadmissible: social media 
posts must always display a full product profile when 
naming a drug online 
- A consumer survey’s post-hoc study is not 
considered sufficient evidence for advertising claims.  
- Can discuss investigational uses of the drugs in an 
appropriate manner, but no off-label promotion 
Canada 
- Pharmaceutical Advertising 
Advisory Board (PAAB) 
- Health Canada’s Health 
Products and Food Branch 
 
- Health Canada’s general 
advertising policies are intended 
to apply to social media 
- PAAB Code Review 2012, 
“Section 6.5: Online Activities” 
- Latest update in 2012 appears 
to cover much of the industry 
- Once a website is determined to be 
advertising, the site in its entirety, including 
any user-generated content, is subject to 
regulatory control  
 
Source: Adapted from Aitken, Altmann and Rosen (2014), p. 8 
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However, and in accordance to Rollins and Perri (2013), pharmaceutical 
companies and their marketing departments must implement social media in their 
routines. These two authors further explain that pharmaceutical marketers must be aware 
that the days of television transmission and physician influence in the behaviour of 
consumers are condemned. Albeit this new approach could be difficult to manage in the 
near future, a well-managed social media platform will allow the creation of consistent 
customer-marketers relationship and will bring significant benefits to pharmaceutical 
companies beyond the simple benefits of a one-way communication (Rollins & Perri, 
2013). 
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2.4.1. Types of digital relationships 
Shankar and Li (2014) reports that the Web and social networks are modifying the 
pharmaceutical industry through their power of influence. For these authors, the internet 
has naturally transformed into a fundamental piece of the search for clinical information 
performed by physicians and patients.  
According to Shankar and Li (2014), the online social networking is being adopted 
by physicians in order to interact with other colleagues. Physicians are using online 
platforms such as Sermo (the largest physician networking platform), Ozmosis, Social 
MD and DoctorNetworking, which are growing at a rapid pace (Shankar & Li, 2014). 
These authors state that the main reasons for the adoption of these online platforms by 
physicians are the possibility to share opinions and discuss medical practice issues with 
other physician colleagues, and learn from most experienced colleagues. Shankar and Li 
also found that physicians are using online platforms to reach patients. Platforms such as 
Facebook, Twitter and blogs are used by physicians to interact with patients to share 
counsels, patients’ past experiences and explanations about treatment procedures 
(Shankar & Li, 2014).  
The online information and the social media are integrating the routine of patients 
who want to manage their health issues. (Shankar & Li, 2014; Davies, 2008). In 2008, the 
internet has become the first choice for retrieving health information, surpassing the 
physicians as a primary source (Manhatan Research, 2008 cited in Shankar & Li, 2014, 
p. 481). The study “Pew Research Center’s Internet & American Life Project” that was 
based on interviews with 3001 adults living in the USA (74% of them used the internet) 
found: (1) 80% of the internet users have searched information about certain diseases or 
treatments; (2) 24% of the internet users (corresponding to 18% of adults) have seen 
online reviews of medicines or treatments while only 4% posted their personal 
testimonials about medicines or treatments; (3) of the 62%  adult internet users (46% of 
the total adults) who use social network sites, only 15% have taken some health 
information from these platforms (Fox, 2011). The “PwC HRI Social Media Consumer 
Survey” that was based on 1060 consumers living in the USA found: (1) 42% used social 
media to find reviews of consumers about health (12% related with medication or  
treatments, 11% with physicians, 10% with hospitals and other healthcare facilities, and 
9% with insurance companies related to healthcare); (2) 32% used social media to search 
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for past health experiences of friends and family; (3) 29% searched for other patients’ 
testimonials related to their diseases; (4) 24% obtained health care information through 
videos or images posted by other patients on social media (PricewaterhouseCoopers 
Health Research Institute, 2012). In a study that involved more than 22,000 Americans 
found that one in each five respondents said that social media platforms provide them 
healthcare information. Of these respondents, 94% stated that Facebook was the primary 
source of information, 32% preferred YouTube, and 18% used Twitter as a first source 
(National Research Corporation, 2011 cited by Shankar & Li, 2014, p. 481).  
Shankar and Li (2014) reported that patients are having energetic interventions in 
several online communities. These authors state that they are sharing positive and 
negative opinions (e.g. adverse effects) of medicines, and also have access to testimonials 
of patients in similar conditions. According to Shankar and Li (2014), the social 
networking site named PatientsLikeMe promotes the interaction between patients in 
similar health conditions in order to share their experiences with their diseases and 
treatments. HealthChapter, IMedfix, Inspire, Disaboom and DiabeticConnect are other 
patients’ online communities (Shankar & Li, 2014). 
Although social media platforms raise several difficult issues for pharmaceutical 
companies, they are still adopting these platforms (Shankar & Li, 2014). For example, 
the pharmaceutical company Pfizer established a deal with Sermo that allows physicians 
to access the company’s clinical data and in the other hand, allows Pfizer to interact 
directly with physicians of the online community (Anon, 2007 cited in Alkhateeb, 
Clauson & Khanfar, 2008). The formation of this kind of relationship can allow 
pharmaceutical companies to alter prescription routines of member physicians 
(Alkhateeb, Clauson & Khanfar, 2008). Also, the Baxa Corporation, not only possess a 
corporate Facebook named “Culture of Safety”, but also a “LinkedIn Business Group” 
(Shankar & Li, 2014).  
The authors report that the Johnson & Johnson Company bought the online 
community named “Children with Diabetes”, and provides support to Facebook pages 
like ADHD-MOM, Johnson’s Baby and Neutrogena. This company also has an active 
Twitter account, with more than 6 million followers and a YouTube channel (Shankar & 
Li, 2014).  
The Genentech Inc. also established a 5-year collaboration with the 
PatientsLikeMe platform, in order to have access to patients’ experiences related to health 
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issues (Adams, 2014). Other companies like GlaxoSmithKline and Sanofi-Aventis started 
their presence on Facebook in 2011 (Meyers, 2012). For example, Pfizer’s Facebook page 
had 21,832 “likes” in April 2011 (Meyers, 2012), while in April 2014 had 103,630 “likes” 
(Pfizer, 2014). In this page, the company was, at the time of author’s writing, focused on 
posts related to science, to corporate information, and corporate social responsibility 
(Meyers, 2012). According to this author, Pfizer didn’t allow users to post on its Facebook 
page.  
Another big company, Novartis, has a Facebook page that had in April 2011 5,076 
“likes” (Meyers, 2012), while in April 2014 it had 51,521 “likes” (Novartis, 2014). At the 
time of the author’s writing, the majority of posts on Novartis’ Facebook page were 
related to the company (Meyers, 2012). AstraZeneca also possesses a Facebook page 
named AstraZeneca US Community Connections that had 14,862 “likes” in April 2014 
(AstraZeneca, 2014), while in April 2011 had only 10,049 “likes” (Meyers, 2012). This 
Facebook page shares similarities with Pfizer’s Facebook page in terms of posts and 
restrictions, but there were also posts about politics and healthcare topics focused on 
consumers’ needs (Meyers, 2012).  
 
Table 6 – Utilization of social media platforms by top 20 pharmaceutical companies 
Ranking(a) Company Revenue
(a) 
(million) Blog 
   
Physician or 
patient 
community 
1 Pfizer $58.523 Yes Yes Yes Yes No 
2 Novartis $44.420 No Yes Yes Yes Yes 
3 Merck & Co. $39.811 No Yes Yes Yes Yes 
4 Sanofi $37.403 No  Yes Yes  Yes No 
5 GlaxoSmithKline $36.156 Yes Yes Yes Yes No 
6 AstraZeneca $32.515 Yes Yes Yes Yes Yes 
7 Johnson & Johnson $22.396 Yes Yes Yes Yes Yes 
8 Eli Lilly & Co. $21.685 Yes Yes Yes Yes No 
9 Abbott Laboratories $19.894 No  Yes Yes Yes No 
10 Bristol-Myers Squibb $19.484 Yes No Yes Yes Yes 
11 Teva $16.121 No Yes Yes Yes Yes 
12 Takeda Pharma $14.829 No No Yes No No 
13 Bayer Schering $14.485 No Yes Yes Yes Yes 
14 Boehringer-Ingelheim $12.883 No Yes Yes Yes No  
15 Astellas $11.161 No Yes Yes Yes No 
16 Dalichi-Sankyo $10.794 No No Yes Yes No 
17 Eisai $8.542 No No Yes Yes No 
18 Otsuka Pharmaceutical $8.440 No No Yes No No 
19 Gilead Sciences $7.390 No No Yes Yes Yes 
20 Mylan $5.404 No No Yes No No 
Note: 
(a) Top 20 pharmaceutical companies based on 2010 revenues (revenue source: ContractPharma.com) 
 
Source: Adapted from Shankar and Li (2014), p. 485 
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According to Heywood et al. (2007) cited in Alkhateeb, Clauson and Khanfar 
(2008), several pharmaceutical companies are trying to take advantage, through online 
DTC advertising, of the adoption of Web 2.0 platforms by patients.  
As seen in Table 6, by the end of 2011, all the 20 most profitable pharmaceutical 
companies in 2010 had a Facebook presence, while 17 had a Twitter account, 13 had a 
YouTube channel, 8 supported online communities and 6 had a blog (Shankar & Li, 
2014). Another study reported by Aitken, Altmann, and Rosen (2014) and developed in 
2014 by IMS Institute for Healthcare Informatics revealed that of the top 50 
pharmaceutical companies assessed, only 10 companies had simultaneous presence on 
Facebook, Twitter and YouTube. They further discovered that only 22 had a Twitter 
account, 17 had a YouTube channel, while 15 had a Facebook presence. 
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2.4.2. Changes in the communication  
 Back in 2011, Pantaleoni believed that, the Web 2.0 was present in the lives of 
youngsters born in the 90s. This author states that for these youngsters this web is a natural 
channel of communication, like was the telephones for previous generations. In this way, 
users have accepted naturally the social networks. Pantaleoni states that in the year 2009, 
there was a blast of social networks’ users. Nowadays, social networks like Facebook, 
LinkedIn and Twitter are the source of news and communications for the worldwide 
population (Pantaleoni, 2011).  
According to Goswami et al. (2013), social media provides value to companies 
through the development of a relationship between the brand and the online networking 
community. These authors state that it is important for companies to integrate online 
networks in order to manage effectively the relationship with customers (through 
marketing strategies that are proactive and nonreactive). In a business-to-consumer 
scenario, it is important to create an empowered relationship (Goswami et al., 2013). 
According to Camacho (2014), patients have fewer restrictions when they are trying to 
find health care information. With the internet, the searches for this type of information 
have become an ordinary activity, contributing for the rise of patient empowerment 
(Camacho, 2014). 
Rollins and Perri (2013) suggested that a successful marketing strategy depends 
on the communication processes. For achieving this success it is necessary to 
communicate positive attributes of products, answer to questions and doubts and adapt 
the message when the consumer and competitor behaviour changes. In traditional 
marketing, the communication was based on a monologue (one-way communication), 
where television and print advertisements were developed to transmit highly specific 
messages at key moments (Rollins & Perri, 2013). Through social media platforms, the 
possibility of a dialogue was implemented, allowing customers to participate with 
questions and doubts while the brand has the possibility to establish a relationship with 
these customers (Rollins & Perri, 2013; Shankar & Li, 2014).  
According to Bonet and Garrote (2011) and Davies (2008), the webs of health 2.0 
provided patients with the possibility of having interactions with people with common 
interests and clinical situations, as well as the access to mixed networks composed of both 
healthcare professionals and patients. These authors affirm that patients are choosing 
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what, when and how to share information about their symptoms, treatments (including 
opinions about physicians), healthcare facilities, medicines, etc. They further state that 
patients’ filiations and participation in online communities enhance their positive thinking 
and offer emotional support.  
Another important role of social networks (related to health) is their ability to 
promote prevention (Bonet & Garrote, 2011; Davies, 2008). According to Camacho 
(2014) and Shankar and Li (2014), social media platforms are becoming a main channel 
for communication between pharmaceutical companies and patients/customers, allowing 
an accessible dialogue between them. For example, the Vice-President of Genentech’s 
Medical Affairs department stated that the recent agreement with PatientLikeMe.com 
platform will possibly improve the engagement of healthcare providers and allow to listen 
to patients (Adams, 2014).  
Still, one big concern for pharmaceutical companies regarding social media is the 
fact that they are forced to follow all patients-generated content, especially because of the 
consequences that may arise with adverse effects posting and other negative situations 
(Camacho, 2014). This author completes his previous idea by stating that harmful 
opinions about medicines can lead to problematic situations that are difficult to manage 
for any pharmaceutical company’s brand manager.   
According to Brown, Broderick and Lee (2007), word of mouth (WOM) 
communication is considered to be a major form of online interactions between 
consumers, especially in online communities. These authors state that WOM is a channel 
of communication where the consumer is the prime intervenient and is independent of the 
market. For this reason, this type of communication is more accepted than the 
communication made by pharmaceutical companies towards patients. (Schiffman & 
Kanuk, 1995; Arndt, 1967 cited in Brown, Broderick & Lee, 2007). When comparing 
traditional marketing communications with WOM, this last presents itself as having 
higher influence in the opinion of products, development of attitudes and decision-making 
processes (Herr, Kardes & Kim, 1991; Bone, 1995 cited in Brown, Broderick & Lee, 
2007). Marketers need to realise that the brand control is shared with consumers who 
wish to develop a fertile dialogue with them (Brown, Broderick & Lee, 2007). For Trusov, 
Bucklin and Pauwels (2009), WOM marketing occurs notably in the internet. These 
authors state that not only does the internet provides the possibility for consumers to share 
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opinions and experiences between them, it also allows companies to take advantage of 
WOM (e.g. WOM can be less expensive than traditional advertising). 
According to Shankar and Li (2014), with the social media (e.g. social networks), 
researchers started to dedicate more of their time to WOM occurring online instead of the 
offline WOM settings. These authors state that there are three main differentiating factors 
between online and offline settings: (1) WOM in social media is of easy access and more 
scalable than WOM offline mode. It is clear that user-generated content in social media 
can reach a vast number of users, while in the offline settings is restricted to interpersonal 
communications; (2) WOM in social media can influence more than WOM in offline 
context because the information underlined in the messages of people with the same 
interests is perceived to be more credible; (3) WOM in social media is not confined to 
one place as it is the case of WOM in offline settings. Because this WOM occurs on the 
internet, it can reach users in any place at any time with no restrictions. 
These same authors stated that “in the pharmaceutical industry, WOM influence 
can emanate from different players such as patients, physicians, healthcare providers, 
insurers, regulatory authorities, general public, and others” (Shankar & Li, 2014, p. 489).  
 
Figure 9 – How WOM helps in the sales funnel 
 
 
Source: Adapted from Shankar and Li (2014), p. 498 
 
However, these authors conclude that there is not a consensus in the studies 
regarding the influence of WOM in the pharmaceutical environment. For them, it is clear 
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that it is necessary additional studies in order to provide marketing insights about this 
subject to pharmaceutical companies (Shankar & Li, 2014).  
Nevertheless, social media can have a crucial role in the sales funnel (see Figure 
9), since it “can enhance effectiveness of the sales funnel’s different stages such as lead 
generation, lead qualification, persuasion, customer relationship management, and 
support” (Shankar & Li, 2014, p. 498). 
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2.4.3. Online engagement  
According to Goswami et al. (2013), there is a concept that is being used by 
companies in order to direct their customers to their websites. They further explain that 
this concept, which was defined as “user engagement”, consists in retaining customers 
through websites, using quality content.  
Along with Haven, Vittal, Overby, Favier and Cokeh (2008), user engagement is 
composed of four “I’s” (p. 3):  
 
• “Involvement” (“the presence of a person at the various brand touchpoints”);  
• “Interaction” (“the actions people take while present at those touchpoints”);  
• “Intimacy” (“the affection or aversion a person holds for a brand”);  
• “Influence” (“the likelihood a person is to advocate on behalf of the brand”)  
 
Therefore, Itskhoki (2011) claimed that the relationship between social media and 
pharmaceutical companies is not easy to manage. However, this author affirms that 
marketers of prescription and OTC medicines are using social media, even though not as 
aggressively as in traditional advertising. Itskhoki further explains that social media gives 
the opportunity to pharmaceutical companies to listen to consumers while allowing a 
development of a relationship. People not only are using social media to interact with 
their friends but they also manifest their interest in brands by becoming their fans. 
According Itskhoki (2011), through a tool named “MultiMediaMentor®” developed by 
Knowledge Networks it was possible to verify that in 2011, 28% of the USA population 
between 13 and 80 years old were regular users of social media, while the correspondent 
percentage for consumers who bought prescription and OTC medicines was 26% and 
28% of the total population, respectively.  
To Itskhoki (2011), mobile technology has brought significant changes to social 
media use. In 2011, 40% of social media users stated that they used mobile technology to 
interact on social media, while in 2010 this value was only 28%. This author affirms that 
these users search information (e.g. prices and brand reviews) through social media when 
purchasing on-site. This scenario is quite interesting for marketers of OTC medicines 
because it can lead to more power of influence over consumers’ choice in this type of 
purchasing (Itskhoki, 2011). 
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Itskhoki (2011) also referred a study named “The Faces of Social MediaSM”, 
which identifies six segments of social media users, with each one of them possessing 
singular aspects (see Figure 10).  
 
Figure 10 – Social media segments (% population 13-80 years old (USA))  
  
 
Source: Adapted from Itskhoki (2011), p. 2 
 
The “Evangelists”, “Highly Influenced Active Users” and “Low Influenced 
Active Users” segments are composed of youngsters that are actively posting and 
reviewing brands, while the “Highly Influenced Passive Users”, “Low Influenced Passive 
Users” and “Non-Users” segments are associated with older users. These segment 
dimensions are reproduced when analysing only users of prescription and OTC medicines 
(Itskhoki, 2011). 
In a study titled “IBM Institute for Business Value Benchmarking Program - Sales 
and marketing Study” developed by IBM in the beginning of  2011, several sales and 
marketing managers (88 from pharmaceutical companies) were inquired. According to 
retrieved data (see Figure 11), the pharmaceutical sector is far behind in terms of social 
media engagement when comparing to other industries (Liu & Fraser, 2012).  
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Figure 11 – Does your company engage potential or current customers via social media? 
 
 
Source: Adapted from Liu and Fraser (2012) 
 
According to PricewaterhouseCoopers Health Research Institute (2012), in a 
study of 2012 titled “PwC HRI Social Media Consumer Survey”, 1,060 adults living in 
the USA where inquired, leading to several findings: (1) more than 80% of the 
interviewed individuals between 18 and 24 years old will probably share health 
information through social media and 90% of the same individuals will engage in health 
activities in these same platforms; (2) only 45% of the inquired individuals between 45 
and 64 years old consider to share health information and 56% probably will engage in 
social media; (3) Only 16% of the inquired admitted to use social media to review 
medicines or treatments; (4) 43% of the questioned individuals consider to share a 
positive experience with medicines and treatments, while 38% will share a negative 
experience; (5) 23% of the respondents expect an answer within an hour when requesting 
information to a health company through social media, while 42% expect an answer 
within few hours and 70% expect an response within a day; (6) when posting a complain 
through social media about a service, product or experience related to a health company, 
22% of the respondents stated they expect an answer within an hour, 29% expect a reply 
in few hours and 66% hoped to have an answer within a day; (7) 34% of the inquired 
affirm that social media can influence their decision about taking a medicine.  
In terms of pharmaceutical companies’ presence in social media, the “PwC HRI 
Social Media Consumer Survey” found that: (1) 68% of the inquired individuals would 
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like the presence of discounts and coupons; (2) 65% of the respondents consider 
interesting the possibility that social media brings for making complains and access 
customer support; (3) 58% and 60% of the respondents thought that was interesting 
having reminders for appointments and treatments, respectively; (4) 65% found value in 
information that could help find the cheapest medication; (5) 56% of the respondents felt 
that it is interesting having support groups for similar patients; (6) 53% saw value in the 
possibility of sharing positive experiences with other patients; (7) 42% of the interviewed 
people supported games and contests that could encourage healthy behaviours. However, 
the data retrieved also showed: (8) only 37% of the respondents will probably trust in the 
information made available through social media by pharmaceutical companies, while 
only 28% will share it.  
According to PricewaterhouseCoopers Health Research Institute (2012), in the 
study “HRI Week in the Life Of Analysis”, developed in 2012, the interactions between 
consumers and pharmaceutical companies through the company’s Facebook page were 
assessed and conclusions point that consumers interactions are divided as: (1) 5% made 
questions; (2) 48% provided feedback, (3) 47% shared and developed conversations in 
the online platform. On the other hand, the pharmaceutical companies: (4) 35% of them 
provided information through their Facebook page; (5) 8% developed promotional 
activities; (6) 57% shared and developed conversations in the online platform.  
In this same study, several social media where analysed leading to several findings 
(see Figure 12): (1) pharmaceutical companies’ social media have less activity than online 
consumer communities, but when comparing with other healthcare companies they 
possess a higher number of views; (2) the sentiment analysis revealed that a small number 
of social media mentions related to pharmaceutical companies were negative (around 
6%), while neutral mentions were about 81% of the total mentions, leaving only 13% for 
positive mentions; (3) the highest social media activity in the pharmaceutical sector was 
registered when a pharmaceutical company alerted members about a product recall, 
leading to 12 “likes”, 47 shares and 12 comments. 
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Figure 12 – A week in the life of social health (social media) 
 
 
Source: Adapted from PricewaterhouseCoopers Health Research Institute (2012), p. 22 
 
According to Aitken, Altmann, and Rosen (2014), in order to evaluate the use of 
Facebook, Twitter and YouTube by the top 50 pharmaceutical companies, the IMS 
Institute for Healthcare Informatics developed three indices (Reach, Relevance and 
Relationship) that define the global IMS Health Social Media Engagement Index (see 
Table 7).  
 
Table 7 – IMS Health measures and raking for social media engagement 
Ranking IMS Health Reach Index(a) IMS Health Relevance Index(b) 
IMS Health Relationship 
Index(c) 
IMS Health Social Media 
Engagement Index(d) 
1 Johnson & Johnson Johnson & Johnson Johnson & Johnson Johnson & Johnson 
2 GlaxoSmithKline GlaxoSmithKline Novo Nordisk GlaxoSmithKline 
3 Novartis Novartis Bayer Novo Nordisk 
4 Pfizer Pfizer UCB Pfizer 
5 Novo Nordisk Boehringer Ingelheim Hospira Novartis 
6 Boehringer Ingelheim Novo Nordisk GlaxoSmithKline Boehringer Ingelheim 
7 Merck & Co Bayer Boehringer Ingelheim Bayer 
8 Bayer Merck & Co Merck & Co Merck & Co 
9 Merck KGaA Merck KGaA AstraZeneca AstraZeneca 
10 Lilly Lilly Pfizer UCB 
Note: 
(a) Reach is a measure of the absolute number of listeners and the index is based on the number of people reached by each channel through likes, 
shares and re-tweets on Facebook, Twitter and YouTube   
(b) Relevance measures whether people found posts or content relevant and/or useful, and the index is based on the extent to which content is being 
shared and forwarded across social networks 
(c) Relationship is a measure of interaction - the back and forth of conversation - and a measure of company and consumer or patient integration, 
while the index measures the level of interaction between a company and those who post, reply or otherwise interact with the company’s postings 
(d) This index results of the combination of all three indices (Reach, Relevance and Relationship). To reflect the different importance and usages of 
social media, each index was weighted by a factor of 1, 2 and 4 for the Reach, Relevance and Relationship indices respectively The Index reflects 
the current overall usage of social media by pharmaceutical companies on healthcare related topics 
 
Source: Adapted from Aitken, Altmann and Rosen (2014) 
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Aitken, Altmann and Rosen further state that the companies composing the global 
index are specialized, have a big presence in the consumer health business and generate 
large amounts of revenue. For them, medium size companies can compete with large ones 
in terms of social media engagement because they are more flexible and have reduced 
audiences (see Relationship index in Table 7). Johnson & Johnson’s high performance on 
social media is clearly distinguished from the performance of other companies in the 
indices, revealing a lack of maturity of pharmaceutical companies towards social media 
adherence (Aitken, Altmann, and Rosen, 2014).  
Elsevier Pharma Solutions (2012) referred that physicians use different social 
media platforms. Through Table 8 it is possible to verify that YouTube is the platform 
mostly used by the inquired physicians in the study. Physician communities are the 
preferred channel in United Kingdom and Italy while French and Spanish physicians use 
more YouTube. Twitter reveals itself as the least used platform. It is clear that physicians 
use more physician communities for professional-related issues, while Facebook and 
Twitter register the lowest value regarding this matter.  
 
Table 8 – Social media use by physicians in different countries 
Social media Total
(a) 
 
United Kingdom 
(n=199) 
France 
(n=138) 
Italy 
(n=375) 
Spain 
(n=286) 
Professional 
use(a) 
Personal/professional 
use(a) 
YouTube 73% 75% 77% 64% 80% 3% 33% 
Physician communities 67% 82% 38% 86% 44% 49% 16% 
Google+(b) 65% 52% 57% 70% 71% 4% 46% 
Facebook 58% 59% 49% 50% 73% 1% 16% 
Blogs 55% 47% 50% 54% 66% 8% 31% 
LinkedIn 38% 35% 21% 45% 43% 22% 11% 
Patient communities 33% 22% 42% 36% 28% 20% 10% 
Twitter 28% 29% 14% 25% 38% 2% 10% 
Note: 
(a) n=1026 
(b) Google+ is probably being perceived as the search engine Google. Therefore this result is directional 
 
Source: Adapted from Elsevier Pharma Solutions (2012) 
 
In a Publicis Touchpoint Solutions (2014) study, 245 physicians using the online 
platform Sermo were interviewed. The data retrieved showed that 63% of the physicians 
also use Facebook, while 40% uses LinkedIn. Far behind in the choices of these 
physicians are Google+ with 20% and Twitter with 19%. 
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2.4.4. Advantages and disadvantages of social media  
Advantages 
 
According to Shankar and Li (2014), pharmaceutical marketing performed 
through social media brings more benefits when comparing to traditional media. These 
authors state that social media platforms allow pharmaceutical companies to be aware of 
the customers’ needs, while engaging them in a two-way communication, allowing 
marketers to retrieve information about the company, products and brands. They also 
affirm that this dialogue allows the establishment of a relationship with influencers.  
Another advantage of social media platforms is the fact that they are a more cost-
efficient approach (almost all of them are free to use) than traditional media. At the same 
time, they allow to communicate with a larger audience and a wider reach when 
comparing to traditional media (Shankar & Li, 2014).  
According to Shankar and Li (2014), social media and traditional media can also 
coexist in a symbiosis, leading to increased revenues and financial returns of a company. 
These authors exemplify this cooperation with a situation of a pharmaceutical company 
(Bristol-Myers Squibb) that used a cartoon in a television advertisement in order to 
promote the anti-depressant medicine named “Abilify”. Several viewers who were fond 
of the cartoon posted the advertisement on YouTube, and in a small period of time the 
video reached around 10,000 views, while in social media platforms such as Twitter and 
Facebook a buzz was created around it. In this way, with social media, it is possible to 
increase brand awareness and attract more viewers towards the advertisement, leveraging 
the television advertising (Shankar & Li, 2014). 
The same researchers suggested that prescription decision-making is surrounded 
by uncertainty and associated with medicine efficacy and risks such as adverse effects, 
and it is leveraged by the different clinical situations that different patients experience 
(Ching, 2010; Narayanan & Manchanda, 2009 cited in Shankar & Li, 2014). For Shankar 
and Li (2014) and Brown, Broderick and Lee (2007), WOM produced by people who 
share similar situations is seen as more trustworthy when comparing to information 
provided by pharmaceutical companies. Shankar and Li (2014) stated that social networks 
allow WOM to flow directly to people with common interests. For them, social media’s 
WOM can influence positively the sales dynamic and the return on investment. 
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Disadvantages 
 
As suggested by Aitken, Altmann and Rosen (2014), the pharmaceutical industry 
has been slow to adopt social media (especially in Europe) because of the highly stressing 
regulatory environment, security issues raised by new technologies and the uncertainty 
of how to engage directly with patients. In the past, regulators have sent warning letters 
that discouraged the adoption of social media by pharmaceutical companies, but there are 
other reasons for this phenomenon (Aitken, Altmann & Rosen, 2014). The main issues 
related to social media adoption from the pharmaceutical industry can be divided in three 
categories: legal, technical and internal. These categories, according to Creation 
Healthcare and Weber Shandwick, “include regulatory compliance, loss of content 
control, privacy concerns, lack of familiarity with social media and proving…[return on 
investment] for social media” (Aitken, Altmann & Rosen, 2014, p. 9). For example, a 
negative Facebook comment can become viral in a short period of time.  
Also, the adverse effects reported in social media and the consequent obligation 
to communicate them to authorities are perceived by pharmaceutical companies as 
restraining measure (Aitken, Altmann & Rosen, 2014). 
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CHAPTER 3 – RESEARCH FRAMEWORK AND METHODOLOGY 
 
Social media is becoming a powerful tool. Not only it helps users to gather 
information, it can also enhance the communication of companies with their customers. 
Nowadays, several companies have marketing strategies developed exclusively for social 
media communication, as they are starting to see the benefits of its use. However, in the 
pharmaceutical industry, the social media thematic is surrounded by doubts raised by the 
absence of official rules and guidance, leading to concerns that are difficult to manage in 
the eyes of this industry. Nevertheless, several pharmaceutical companies are still 
adopting social media even without a clear view of how to proceed. 
According to the literature review, several studies report the activity of 
pharmaceutical companies on social media, especially on Facebook, Twitter and 
YouTube. However, the majority of these studies do not evaluate the digital strategy of 
pharmaceutical companies on such social media platforms. Moreover, only one 
unpublished study from Aitken, Altmann, and Rosen (2014) tries to characterize the 
digital engagement strategy of pharmaceutical companies by establishing an integrated 
engagement raking for Facebook, Twitter and YouTube.  
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3.1. Research Framework 
Without any mature, robust and published conceptual model being applied to the 
pharmaceutical industry, this research tries to follow the footsteps of the Aitken, Altmann, 
and Rosen (2014), however with its own innovative conceptual model that is represented 
in Figure 13. 
 
Figure 13 – Conceptual model 
 
The conceptual model proposed in Figure 13 is based on three essential elements: 
(1) the type of pharmaceutical company regarding its size (revenue and number of 
employees); (2) the digital strategy that each pharmaceutical company puts in place for 
each social media platform; (3) the most relevant social media platforms that are the focus 
of analysis (Facebook, Twitter and YouTube).  
With this conceptual model, it is possible to evaluate possible associations 
between the companies profile with their digital engagement strategy in all the three 
assessed social media platforms. Also it allows verifying if the digital strategy of a 
company is consistent between the social media targeted for analysis.  
With the conceptual model defined, three hypotheses emerged: 
 
H1: The larger the pharmaceutical companies the higher engagement on social media. 
Investment in social media depends on the capability of a company to allocate 
resources to this specific field. Because larger companies generate larger amounts of 
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revenue, they possess larger budgets and human resources numbers that can be used to 
manage social media. As these companies have more means to enhance the social media 
activity, they can reach out their audience better than small companies that do not possess 
the same resources of larger companies. Moreover, Aitken, Altmann, and Rosen (2014) 
found an association between the  company size and their engagement performance. In 
this way, this research tries to give insights of if this association is or is not present on 
Facebook page, Twitter account and YouTube channel of selected pharmaceutical 
companies. 
 
H2: The digital engagement strategy is common in the most popular social media 
platforms (Facebook, Twitter and YouTube). 
The analysis of the level of engagement raises another question: Do 
pharmaceutical companies use the same strategy on Facebook, Twitter and YouTube?  
Considering that companies have limited resources, they can allocate more 
resources only to a social media platform and less to the others. As showed by Shankar 
and Li (2014), not all pharmaceutical companies are present in these three social media 
platforms, especially smaller companies. This research attempts to verify if 
pharmaceutical companies use the same strategy in all three platforms or if they focus 
more on specific platforms. 
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3.2. Research Methodology  
In order to initiate this investigation, it was necessary to define the sample. As the 
subject of analysis was pharmaceutical companies’ presence in social media, the first 
important step was to choose the size of the sample. It was decided to use the top 20 
pharmaceutical companies within a raking of the top 50 pharmaceutical companies (in 
terms of revenue) elaborated by Pharmaceutical Executive in 20138.  
After defining the size of the sample, the social media (Facebook, Twitter and 
YouTube) presence of the top 20 pharmaceutical companies was analysed by visiting 
their global homepage in order to search for evidence of their adherence to social media. 
When the homepage did not have a reference to social media adherence, other official 
websites of the companies (e.g., websites of companies in specific countries) were visited 
and analysed (see Annex I). At the same time, social media platforms of these 
pharmaceutical companies were visited, where a list of links was elaborated for each 
platform in order to facilitate the next steps of the investigation (see Annex II, III, and 
IV). When there were several social media channels for the same social media platform, 
only one was chosen (except for the case of Roche, because Genentech - company from 
Roche Group - was included). In these choices, the most relevant criteria for inclusion 
were the fact that these channels were associated with healthcare. Also, when a company 
did not have a global social media channel, a country-specific channel was considered 
and added to the list. 
With all the data provided through the listing of websites, it was possible to initiate 
a second phase of the analysis. This phase consisted in the analysis of each and every 
social media platform for each pharmaceutical company using tools provided by two 
websites: www.simplymeasured.com9 (for Facebook and Twitter) and 
www.socialbakers.com10 (for Facebook and YouTube).  
The SimplyMeasured tool for collecting data from Facebook pages was “Free 
Facebook Fan Page Report”, while for Twitter accounts was “Free Twitter Customer 
Service Analysis”. Because these tools have time frame restrictions, two distinguished 
8 The Pharmaceutical Executive article can be found at 
http://www.imsconsultinggroup.com/deployedfiles/consulting/Global/Content/How%20We%20Help/Stra
tegy%20&%20Portfolio/PharmExec-pharma50.pdf 
9 http://simplymeasured.com/free-social-media-tools 
10 http://www.socialbakers.com/bookmarks/ 
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periods of time were analysed (see Table 9). These tools retrieved data (in a form of a 
report) that was possible to analyse through Excel (Microsoft Office tool). The 
Socialbakers tool is a built-in website tool that provided several data for each 
pharmaceutical company’s Facebook page (country of origin of fans in percentage) and 
YouTube channel. 
Table 9 – Facebook and Twitter data collection method 
Platform Tool Period number Period of time 
 
“Free Facebook Fan Page Report” 
1 29 May 2014 to 12 June 2014 
2  14 June 2014 to 27 June 2014 
 
“Free Twitter Customer Service Analysis” 
1 5 June 2014 to 12 June 2014 
2 20 June 2014 to 26 June 2014 
 
With all information collected, the next step was to export the most relevant data 
to Excel. By accomplishing this step, it was possible to execute several Excel tools in 
order to analyse efficiently the data.   
For the data retrieved from SimplyMeasured, the two periods of time were 
aggregated into one, being this last one the major target of analysis. Because it was 
necessary more socioeconomic data from the pharmaceutical companies, employee data 
was collected from different sources and integrated in the Excel files (see Annex V). 
 
Table 10 – Engagement formulas 
Platform Engagement formulas 
    
𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝑃𝑃𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑃𝑃𝑒𝑒𝑃𝑃𝑒𝑒𝑒𝑒 = "𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝑇𝑇𝑒𝑒𝑃𝑃𝑇𝑇𝑃𝑃𝑒𝑒𝑒𝑒 𝐴𝐴𝐴𝐴𝑃𝑃𝐴𝐴𝑒𝑒 𝑇𝑇ℎ𝑃𝑃𝑖𝑖"
𝑒𝑒º 𝑃𝑃𝑜𝑜 𝐹𝐹𝑒𝑒𝑒𝑒𝑖𝑖  
𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝑒𝑒𝑒𝑒𝑃𝑃 𝑇𝑇𝑃𝑃𝑒𝑒𝑒𝑒𝑃𝑃 𝑃𝑃𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑃𝑃𝑒𝑒𝑃𝑃𝑒𝑒𝑒𝑒 = 𝑒𝑒º 𝑃𝑃𝑜𝑜 𝑃𝑃𝑃𝑃𝑖𝑖𝑒𝑒 + 𝑒𝑒º 𝑃𝑃𝑜𝑜 𝑆𝑆ℎ𝑒𝑒𝑃𝑃𝑃𝑃𝑖𝑖 + 𝑒𝑒º 𝑃𝑃𝑜𝑜 𝐿𝐿𝑃𝑃𝑇𝑇𝑃𝑃𝑖𝑖 + 𝑒𝑒º 𝑃𝑃𝑜𝑜 𝐶𝐶𝑃𝑃𝑒𝑒𝑒𝑒𝑃𝑃𝑒𝑒𝑒𝑒𝑖𝑖
𝑒𝑒º 𝑃𝑃𝑜𝑜 𝐹𝐹𝑒𝑒𝑒𝑒𝑖𝑖  
 
𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝑒𝑒𝑒𝑒𝑃𝑃 𝑇𝑇𝑃𝑃𝑒𝑒𝑒𝑒𝑃𝑃 𝑃𝑃𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑃𝑃𝑒𝑒𝑃𝑃𝑒𝑒𝑒𝑒 = 𝑅𝑅𝑃𝑃𝑒𝑒𝑅𝑅𝑃𝑃𝑃𝑃𝑒𝑒𝑖𝑖 + 𝑀𝑀𝑃𝑃𝑒𝑒𝑒𝑒𝑃𝑃𝑃𝑃𝑒𝑒𝑖𝑖 (𝑃𝑃𝑒𝑒𝑖𝑖𝑃𝑃𝐴𝐴𝑃𝑃𝑃𝑃𝑒𝑒𝑒𝑒 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑖𝑖)
𝑒𝑒º 𝑃𝑃𝑜𝑜 𝐹𝐹𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑅𝑅𝑃𝑃𝑃𝑃𝑖𝑖  
 𝑇𝑇𝑃𝑃𝑒𝑒𝑒𝑒𝑃𝑃 𝑃𝑃𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑃𝑃𝑒𝑒𝑃𝑃𝑒𝑒𝑒𝑒 = 𝑉𝑉𝑃𝑃𝑃𝑃𝑅𝑅𝑖𝑖 𝑃𝑃𝑃𝑃𝑃𝑃 𝑣𝑣𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃
𝑒𝑒º 𝑃𝑃𝑜𝑜 𝑆𝑆𝐴𝐴𝐴𝐴𝑖𝑖𝑖𝑖𝑃𝑃𝑃𝑃𝐴𝐴𝑃𝑃𝑃𝑃𝑖𝑖 
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With all data collected, the next step was to calculate the engagement in each 
platform for each pharmaceutical company, according to the formulas demonstrated in 
Table 10. 
Another important tool for analysing specific data related to Facebook and Twitter 
was provided by www.tagxedo.com11, which consists in presenting a visualization of the 
most frequent words in the analysed texts (comments, posts and tweets). Also some data 
from Excel files were exported to SPSS statistics software in order to run descriptive 
statistics (Crosstabs) and also multivariate statistics (Hierarchical Cluster Analysis). The 
first step was to define how many clusters exist for each social media platform. To 
perform this step the tool “Hierarchical Cluster Analysis” of SPSS was used, using as 
variables the “Engagement” for each social media platforms and the variable “Fans” for 
Facebook, “Followers” for Twitter and “Subscribers” for YouTube (see Annex VI). All 
of the analysis was performed according to Ward’s method.  
With the clusters created for each social media platforms, it was time to define 
their designations. Using the “Crosstabs” tool of SPSS, the same two variables were again 
analysed in function of each cluster for each social media platforms. Through this, each 
cluster received a designation (see Annex VII). 
Given that all clusters were identified and named, a more profound analysis was 
made using more variables, in order to characterize each cluster. For this analysis, the 
“Crosstabs” tool was used in the same way for the definition of clusters designations (see 
Annex VIII, IX, X). 
 
 
11 http://www.tagxedo.com/app.html 
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CHAPTER 4 – DATA TREATMENT AND RESULTS 
 
In this research, top 20 pharmaceutical companies by revenue were analysed. In 
Figure 14, a relationship between revenue and company’s employees was established, 
demonstrating that, in general, companies with larger amounts of revenues have also more 
employees.  
The company with the highest revenue amount was Pfizer while the lowest was 
Gilead Sciences. On the other hand, the company with the larger number of employees 
was Novartis while Gilead Sciences continues to be in the bottom also for the number of 
employees.  
 
Figure 14 – Pharmaceutical firms analysed: Socioeconomic profile 
 
 
When analysing social media presence of the top 20 pharmaceutical companies, 
several conclusions were taken. According to Figure 15, 14 (70%) companies have a 
Facebook page (Johnson & Johnson has Facebook page but was not analysed due to 
method’s restrictions), 18 (90%) have a Twitter account, while 15 have a YouTube 
channel.  
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Figure 15 – Pharmaceutical firms analysed: Social media presence 
 
 
Of the companies examined, only 12 (60%) are in all social media platforms 
analysed, while merely 2 (10%), namely Takeda and Daiichi-Sankyo pharmaceutical 
companies, are completely absent on such platforms. 
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4.1. Facebook data analysis 
To evaluate the presence of pharmaceutical companies on Facebook, it is 
important to identify each of the companies that have adhered to this platform.  
In Figure 16, all the 14 companies which have a Facebook page are represented. 
However, it is important to clarify some details related to two companies. The 
pharmaceutical company Johnson & Johnson is highlighted because it was not possible 
to analyse its Facebook presence due to method’s restrictions. On the other hand, it was 
included the company Genentech (part of Group Roche) in the Roche analysis, because 
it is responsible for the most successful medicines of Group Roche. Another important 
aspect is the fact that Roche’s and Abbott’s Facebook pages are dedicated to careers, 
while AstraZeneca’s and Sanofi’s Facebook page are dedicated to USA population. 
 
Figure 16 – Pharmaceutical firms analysed on Facebook 
 
 
Fans 
 
One important step in this research was to analyse pharmaceutical companies in 
terms of number of fans (likes in Facebook page). According to Figure 17, there are 4 
companies that have achieved a number of fans greater than 100.000. The leading 
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company in this category was Novo Nordisk with 176.733 fans. On the other hand, 3 
companies had a number of fans inferior to 10.000. The company with the least number 
of fans was Roche (Genentech), with a total number of fans of 5.832. 
 
Figure 17 – Pharmaceutical firms analysed on Facebook: Page fans 
 
 
After defining the number of fans of each company, it was important to verify the 
country of origin of fans. According to Table 11, at the time of retrieval of the data from 
www.socialbakers.com, all the companies were composed by fans that came from more 
than 4 countries.  
The Facebook pages that are dedicated to USA residents (AstraZeneca and Sanofi) 
have the majority of fans from USA but also have fans from other countries. Some of the 
companies also appear to have a connection between their headquarters and the majority 
of fans’ country of origin (Merck & Co., Roche (Genentech), GlaxoSmithKline, Eli Lilly 
and at some point Teva). According to these findings, the concerns (e.g., DTC 
advertising) raised by the fact that social media can reach countries where Facebook pages 
are not intended, are without any doubt factual. 
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Table 11 – Pharmaceutical firms’ Facebook fans: country of origin 
Company Headquarters 
Country of origin of fans (Facebook) (%)(a) 
1º 2º 3º 4º 
Pfizer USA Egypt 19,6% 
USA 
13,5% 
India 
9,5% 
Brazil 
4,7% 
Novartis Switzerland Egypt 17,5% 
India 
10,6% 
USA 
8,7% 
Brazil 
8,6% 
Merck & Co. USA USA 30,9% 
India 
8,5% 
Egypt 
5,9% 
Brazil 
4,5% 
Sanofi France USA 65,3% 
Brazil 
3,7% 
Egypt 
3,6% 
Algeria 
2,6% 
Roche Switzerland Egypt 29,5% 
USA 
9,5% 
Germany 
7,4% 
India 
5,8% 
Roche (Genentech) USA USA 75,4% 
India 
3,2% 
United Kingdom 
1,6% 
Egypt 
1,2% 
GlaxoSmithKline England United Kingdom 33,3% 
Egypt 
10,3% 
India 
7,4% 
Pakistan 
6,4% 
AstraZeneca England USA 64,7% 
Egypt 
7,9% 
India 
3,3% 
Brazil 
2,1% 
Abbott Laboratories USA India 32,3% 
USA 
12% 
Brazil 
7,9% 
Egypt 
5,2% 
Eli Lilly USA USA 43% 
Brazil 
6,3% 
India 
5,5% 
Egypt 
3,8% 
Teva Israel USA 18,1% 
Israel 
16,9% 
India 
9,0% 
Hungary 
5,9% 
Bayer Germany Mexico 15,6% 
Italy 
13,7% 
Pakistan 
12,7% 
Egypt 
12,4% 
Boehringer Ingelheim Germany Egypt 18,9% 
Pakistan 
16,4% 
Philippines 
16,2%  
India 
7,3% 
Novo Nordisk Denmark Algeria 35,8% 
Indonesia 
15,6% 
Egypt 
12,5% 
Peru 
9,1% 
Note: 
(a) Data retrieved from www.socialbakers.com (19/05/14) 
 
Posts  
 
The activity on Facebook in terms of posts was also assessed. There are two 
categories of posts registered: (1) user posts; (2) brand posts. According to Figure 18, 
only 6 Facebook pages (Merck & Co., Roche, Abbott, Bayer, Boehringer Ingelheim and 
Novo Nordisk) had user posts on their wall, with each one having its own differentiated 
activity.   
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Figure 18 – Pharmaceutical firms analysed on Facebook: Users posts 
 
 
In terms of brand posts, all Facebook pages analysed have brand posts in their 
wall. According to Figure 19, the company which had the highest activity was Boehringer 
Ingelheim with 73 posts while the two companies with the lowest activity were Roche 
(Genentech) and AstraZeneca, both with 10 posts. 
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Figure 19 – Pharmaceutical firms analysed on Facebook: Brand posts 
 
 
After analysing the quantity of brand posts per company, a qualitative analysis of 
these posts was made. According to Figure 20, the majority of brand posts were in a form 
of photo, totalizing 198 (59%) posts. In second place are posts with links, with 79 (24%) 
posts. The least frequent form of posting was in a form of status posts and video, with 9% 
and 8%, respectively. 
 
Figure 20 – Pharmaceutical firms analysed on Facebook: Brand posts type 
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In order to have a precise qualitative analysis of brand posts, another comparison 
was made. In Figure 21, it is possible to observe the type of brand post per company. It is 
clear that the choice for each type of brand post is company-dependent, meaning that 
some companies can post more one type and less another type. Also there are companies 
that do not post some types of brand posts. 
 
Figure 21 – Pharmaceutical firms analysed on Facebook: Brand posts type per company 
 
 
Furthermore, to complete the qualitative analysis, the brand posts were analysed 
adopting a content analysis approach and using “Tagxedo - Creator”12 as data treatment 
tool (see Figure 22, Figure 23, Figure 24, Figure 25, Figure 26), which consists in 
presenting a visualization of the most frequent words in the analysed texts. 
  
12 http://www.tagxedo.com/app.html 
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Figure 22 – Facebook brand posts “Tagxedo” (Pfizer, Novartis and Merck) 
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Figure 23 – Facebook brand posts “Tagxedo” (Sanofi, Roche and Genentech) 
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Figure 24 – Facebook brand posts “Tagxedo” (GlaxoSmithKline, AstraZeneca and 
Abbott) 
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Figure 25 – Facebook brand posts “Tagxedo” (Eli Lilly, Teva and Bayer) 
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Figure 26 – Facebook brand posts “Tagxedo” (Boehringer Ingelheim and Novo 
Nordisk) 
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The analysis of the previous “Tagxedo” figures shows that an international patient 
approach is followed by all companies, emphasizing in general the science, new 
programs, diseases and patients’ health. 
 
Comments, shares and likes in brand posts 
 
The interaction with brand posts is made at different levels. The first type of 
interaction analysed is in a form of comments. According to Figure 27, all Facebook 
pages registered comment activity. Furthermore, the company which registered the 
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largest amount of comments was Boehringer Ingelheim, with 1.660 comments, 
corresponding to 76% of all comments registered.  
The second biggest Facebook page in terms of comments was from Roche, with 
208 (10%), demonstrating a large difference between Boehringer Ingelheim and the other 
companies. 
 
Figure 27 – Pharmaceutical firms analysed on Facebook: Comments to brand posts 
 
 
In order to have a more precise analyse of the comments within brand posts it was 
necessary to display the comments per brand post. According to Figure 28, Boehringer 
Ingelheim continues in front with a ratio of 22,74 (50%) comments, Roche continues in 
second place with 5,07 (11%) comments, but a third company (GlaxoSmithKline) 
emerges with 4,69 (10%) comments. Even with this new ratio, Boehringer Ingelheim 
continues to dominate in this category. 
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Figure 28 – Pharmaceutical firms analysed on Facebook: Comments per brand posts 
 
 
As was made for the brand posts, the comments associated to the same posts were 
analysed by “Tagxedo - Creator” (see Figure 29). It seems, in general, that the most 
frequent words appear to be positive rather than negative. 
 
Figure 29 – Pharmaceutical firms analysed on Facebook: “Tagxedo” view of comments 
 
 
 
For a more precise analysis, each “Tagxedo” of each company is displayed in the 
following figures. The analysis shows that not all companies have positive comments, 
with some registering only negative comments (e.g., AstraZeneca and Novo Nordisk). 
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Figure 30 – Facebook comments “Tagxedo” (Pfizer, Novartis and Merck) 
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Figure 31 – Facebook comments “Tagxedo” (Sanofi, Roche and Genentech) 
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Figure 32 – Facebook comments “Tagxedo” (GlaxoSmithKline, AstraZeneca and 
Abbott) 
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Figure 33 – Facebook comments “Tagxedo” (Eli Lilly, Teva and Bayer) 
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Figure 34 – Facebook comments “Tagxedo” (Boehringer Ingelheim and Novo Nordisk) 
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However, when comments were analysed, there were some that were not available 
for visualization. According to Figure 35, of the 2.180 comments registered for all 
Facebook pages, only 1.971 (90%) were possible to visualize. It means that 10% of 
comments were not analysed by “Tagxedo – Creator”, leading to a speculative result. 
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Figure 35 – Pharmaceutical firms comments status on Facebook
 
 
The second type of interaction with Facebook pages that was analysed was shares 
of brand posts. According to Figure 36, all Facebook pages registered shares activity. 
Furthermore, the company which registered the largest amount of shares was Boehringer 
Ingelheim, with 1.074 comments, corresponding to 48% of all shares registered.  
The second biggest Facebook page in terms of comments was from 
GlaxoSmithKline, with 307 (17%), demonstrating again a large difference between 
Boehringer Ingelheim and the other companies. 
 
Figure 36 – Pharmaceutical firms analysed on Facebook: Shares of brand posts 
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As was made for comments, a display of shares per brand post was produced to 
widen the analysis of shares status. According to Figure 37, GlaxoSmithKline takes the 
lead with a ratio of 28,77 (32%) shares, while Boehringer Ingelheim is relegated to second 
place with 14,71 (17%) shares.  
There is also a more homogeneous distribution of shares per brand post between 
companies. As opposed to the comments analysis, there were changes in the positions 
between the leading companies in this category when executing the two types of analysis.  
 
Figure 37 – Pharmaceutical firms analysed on Facebook: Shares per brand posts 
 
 
The third and last type of interaction with Facebook pages that was analysed was 
likes in brand posts. According to Figure 38, all Facebook pages registered likes activity. 
Furthermore, Boehringer Ingelheim dominates this category, with 37.604 comments, 
corresponding to 74% of all likes registered. The other companies’ brand posts possess 
small number of likes when comparing to Boehringer Ingelheim. 
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Figure 38 – Pharmaceutical firms analysed on Facebook: Likes in brand posts 
 
 
When comparing likes in the form of likes per brand posts, the dominant position 
of Boehringer Ingelheim diminishes to 515,12 (38%) likes per brand post, followed by 
other companies such as GlaxoSmithKline, Novo Nordisk and Pfizer register 178,85 
(13%), 165,55 (12%) and 126,58 (9%) likes per brand post, respectively (see Figure 39). 
 
Figure 39 – Pharmaceutical firms analysed on Facebook: Likes per brand posts 
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Engagement 
 
As discussed in the literature, and based on previous operationalization of the 
concept of engagement, we present the results for Facebook engagement considering it in 
two forms: (1) “People Talking About This”/Fans; (2) 
(Posts+Shares+Likes+Comments)/Fans. The first form to be discussed will be “People 
Talking About This”/Fans. 
 
Figure 40 – Pharmaceutical firms analysed on Facebook: Engagement rate period 1 (1) 
 
 
As noticed from the figure above, Facebook engagement does not increases 
proportionally with the firm size. Since one week period analysis is not enough to 
conclude about the true engagement, a second period of activity was analysed.  According 
to Figure 41, the same disproportionality of period 1 maintains, but it appears to show an 
increase of proximity between companies in terms of engagement. 
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  Figure 41 – Pharmaceutical firms analysed on Facebook: Engagement rate period 2 (1) 
 
 
As stated before, a second engagement analysis was performed using a second 
formula. In Figure 42, Facebook engagement for period 1 is represented and it is clear 
that it maintains the same disproportionality of Figure 40. However, it seems that there is 
a higher discrepancy between companies’ engagement. 
 
Figure 42 – Pharmaceutical firms analysed on Facebook: Engagement rate period 1 (2) 
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For the same reasons stated before, a second period was analysed (see Figure 43). 
Again, it appears to exist a lack of proportionality like the other period analysis, but like 
Figure 41 it seems to show an increase of proximity between companies in terms of 
engagement. 
In all period 1 and 2’s analysis, Boehringer Ingelheim and Eli Lilly show the 
widest engagement ring. 
 
Figure 43 – Pharmaceutical firms analysed on Facebook: Engagement rate period 2 (2) 
 
 
After analysing each period, a total engagement (corresponding to the addition of 
period 1 and period 2) calculated using the second formula, was analysed. According to 
Figure 44, Facebook engagement does not increases proportionally with firm’s revenue 
and number of employees. Like in the periods’ analysis Boehringer Ingelheim and Eli 
Lilly are the top performers in terms of engagement. 
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Figure 44 – Pharmaceutical firms analysed on Facebook: Total engagement (2) 
 
 
Since Boehringer Ingelheim was the most engaging pharmaceutical company on 
Facebook, some of the most engaging posts were reproduced in Figure 45. The most 
engaging posts are related to quizzes, special diseases and company’s history. 
 
Figure 45 – Examples of Boehringer Ingelheim most engaging brand posts 
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4.1.1. Facebook cluster analysis 
In this section, a cluster analysis was performed in order to identify each cluster 
on Facebook. After identifying each cluster, they were named according to engagement 
data and the number of Fans. With the clusters identified and named, a characterization 
was performed through several variables. 
Several clusters were identified when performing a “Hierarchical Cluster 
Analysis” on Facebook data. According to Figure 46, four clusters emerged when 
crossing Facebook engagement data with the number of Fans (see Annex VI). 
 
Figure 46 – Facebook cluster analysis 
 
 
After discovering the clusters, a “Crosstabs” analysis was performed with the 
same variables in order to attempt to assign a name to each cluster (see Annex VII). 
According to Figure 47, the names of each cluster are “Fan Appreciators with High and 
Low Activity”, “Fan Friendly with Medium Activity”, “Strongly Active Fan Haters” and 
“Non-Active Fan Lovers”. 
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Figure 47 – Facebook cluster analysis with defined cluster names 
 
 
With all four clusters named, a more profound analysis was carried in order to 
characterize each cluster (see Annex VIII). Through Table 12, it is possible to verify the 
variables used to further characterize each cluster. This characterization reflects the 
performance of each cluster in each parameter, knowing that these clusters are not 
homogeneous and therefore the companies included can have low and high performance 
in the same cluster. 
 
Table 12 – Facebook clusters: characterization 
 
Fan Appreciators with 
High and Low Activity 
Fan Friendly with Low to 
High Activity 
Strongly Active Fan 
Haters 
Non-Active Fan Lovers 
Revenue +++/-- ++/-- ++/- --- 
Employees ++/- +++/- ++/-- --- 
Brand Posts +++/-- +/- ++/-- -- 
Brand Post Shares +++ ++/-- +/--- +/- 
Brand Post Likes ++ +/-- +/--- ++ 
Brand Post Comments +++/- ++/- ++/--- -- 
User Posts +/--- ++/- +/--- +/- 
Note: 
-> Each + sign reveals the positive intensity in each parameter while each – sign reveals the negative intensity in each parameter, because clusters 
are not homogeneous. 
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4.2. Twitter data analysis 
The pharmaceutical presence on Twitter, was composed of 18 pharmaceutical 
companies. In Figure 48, all the 18 companies which have a Twitter account are 
represented. However, it is important to clarify some details related to one company. As 
was the case for the Facebook analysis, the company Genentech (part of Group Roche) 
was included in the Roche analysis, because it is responsible for the most successful 
medicines of Group Roche. Another important aspect is the fact that Teva’s Twitter 
account is directed to Spanish population while Astellas Pharma’s Twitter account is 
dedicated to USA population. 
 
Figure 48 – Pharmaceutical firms analysed on Twitter 
 
 
Followers 
 
The first parameter evaluated in pharmaceutical companies’ presence on Twitter 
was the number of followers. In Figure 49 it is possible to verify that none of the 
companies have reached 100.000 followers, with Pfizer and Novartis leading with 99.709 
and 84.495 followers, respectively. Three companies are below 5.000 followers (Eli Lilly, 
Amgen and Gilead Sciences).  
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When comparing the number of followers with the number of fans (Facebook 
fans, see Figure 17), it appears that followers have a more homogeneous distribution. 
 
Figure 49 – Pharmaceutical firms on Twitter: Number of followers 
 
 
Tweets, retweets and mentions  
 
In order to have a clear view of the activity on Twitter, three important aspects 
were analysed: (1) tweets; (2) retweets and (3) mentions which includes replies. 
Regarding the first one, the analysis was separated in lifetime tweets and tweets registered 
during the periods of analysis. According Figure 50, three companies have high activity 
(over 5.000 tweets) since their Twitter account conception, with Boehringer Ingelheim 
leading with 6.940 (16%) tweets, followed by Johnson & Johnson (6.069 tweets; 14%) 
and Novartis (5.641 tweets; 13%). On the other hand, five companies registered less than 
1.000 lifetime tweets. 
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Figure 50 – Pharmaceutical firms on Twitter: Number of tweets (lifetime) 
 
 
Regarding the total number of tweets registered in period 1 and 2, they are 
registered in Figure 51. Interestingly, the top three companies in lifetime tweets are the 
same for the total number of tweets registered.  
The only difference was that the leading company was Johnson & Johnson with 
179 tweets, corresponding to 21% of the total tweets; and, Novartis (97 tweets; 11%) 
continues in second place, while Boehringer Ingelheim (87 tweets; 10%) was relegated 
to third place. Only two companies (AstraZeneca and Gilead Sciences) registered tweet 
activity inferior to 10 tweets. 
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Figure 51 – Pharmaceutical firms on Twitter: Total of tweets registered 
 
 
Furthermore, to complete the qualitative analysis of tweets, the total tweets 
registered were analysed by “Tagxedo - Creator”13 (see Figure 52, Figure 53, Figure 54, 
Figure 55, Figure 56, Figure 57 and Figure 58). The analysis of these figures reveals that 
pharmaceutical companies tweet about healthcare subjects, such as certain diseases and 
programs. In general, they focus on patients’ healthcare related issues. 
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Figure 52 – Twitter tweets “Tagxedo” (Pfizer, Novartis and Merck) 
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Figure 53 – Twitter tweets “Tagxedo” (Sanofi, Roche and Genentech) 
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Figure 54 – Twitter tweets “Tagxedo” (GlaxoSmithKline, AstraZeneca and Johnson & 
Johnson) 
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Figure 55 – Twitter tweets “Tagxedo” (Abbott, Eli Lilly and Teva) 
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Figure 56 – Twitter tweets “Tagxedo” (Amgen, Bayer and Boehringer Ingelheim) 
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Figure 57 – Twitter tweets “Tagxedo” (Novo Nordisk, Bristol-Meyers Squibb and 
Astella Pharma) 
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Figure 58 – Twitter tweets “Tagxedo” (Gilead Sciences) 
 
Gilead Sciences 
 
 
 
In terms of retweets, it is possible to verify through Figure 59 that the top 3 
companies are the same as the case of the tweets analysis. This top 3 was responsible for 
51% of the retweets registered. The company which retweeted de most was Boehringer 
Ingelheim with 509 retweets, corresponding to 20% of the total retweets registered, 
followed closely by Johnson & Johnson (492 retweets; 20%) and in third place is Novartis 
with 270 retweets, corresponding to 11% of total retweets. Only two companies (Novo 
Nordisk and Gilead Sciences) registered retweet numbers below 20.  
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Figure 59 – Pharmaceutical firms on Twitter: Total of retweets registered 
 
 
While tweets and retweets share some similarities in terms of top performances, 
the mentions analysis reveals that two new companies dominate this category. Before the 
detailed mentions analysis, it is important to state that the number of mentions include 
also replies. According to Figure 60, the top 2 companies in mentions activity were Merck 
& Co with 1.752 mentions, representing 21% of the total number of mentions, followed 
by Roche (Genentech) with 1.198 (14%). These were the only companies that surpassed 
the 1.000 mentions number. Only one company remained (Gilead Sciences) below 100 
mentions. 
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Figure 60 – Pharmaceutical firms on Twitter: Total of mentions registered 
 
 
Customer service 
 
The customer service responses reflect the specific interaction between 
pharmaceutical companies and their twitter users’ requests. According to Figure 61, in 
the total period of analysis, only 11 Twitter accounts customer services have replied to 
their users’ requests. The companies related to these Twitter accounts were Novartis, 
Merck & Co., Roche (Genentech), Roche, GlaxoSmithKline, Johnson & Johnson, Teva, 
Bayer, Boehringer Ingelheim, Novo Nordisk and Astellas Pharma.  
The company most active in this category was Johnson & Johnson with 48 
customer service responses, corresponding to 48% of the total responses. 
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Figure 61 – Pharmaceutical firms on Twitter: Total customer service responses  
 
 
Just as it is important to verify the response activity in terms of number of 
responses, it is also important to evaluate the quality of these responses in terms of 
response time. For this reason, each period was analysed in order to evaluate responses 
times.  
Through Figure 62, it is possible to verify the average response time for each 
Twitter account for period 1. It is clear that the majority of companies who respond to 
their users take more than half a day, while Teva and Boehringer Ingelheim are the only 
companies to take less than one hour to respond. 
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Figure 62 – Pharmaceutical firms on Twitter: Customer service responses - period 1 
 
 
When analysing customer service responses in terms of response time in period 2, 
it is possible to verify that almost all companies take more than 10 hours to reply to their 
users (see Figure 63). However, the exceptions are Boehringer Ingelheim and Astellas 
Pharma with less than 1 hour to respond and Teva which takes about 3 and a half hours.  
Interestingly, in the two periods, the only company to maintain responses in less 
than 1 hour was Boehringer Ingelheim. Also in the period 2, more companies have 
responded when comparing to period 1. 
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Figure 63 – Pharmaceutical firms on Twitter: Customer service responses - period 2 
 
 
Engagement 
 
As made for Facebook analysis, we present the results for Twitter engagement 
considering it as (Retweets+Mentions(including replies))/Followers. 
 
Figure 64 – Pharmaceutical firms on Twitter: Engagement rate period 1 
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The first engagement analysis was made for the period 1 and it is demonstrated in 
Figure 64. According to the graphical display of this figure, the engagement rate does not 
increase proportionally with the company size. However, one company (Teva) seems to 
have a high performance when comparing to the other companies. In order to have a more 
robust engagement analysis, a second period of activity was assessed. According to 
Figure 65 a similar disproportionally is observed for period 2. While in period 1 only one 
company stands out from the others, in period 2 two companies (Teva and Eli Lilly) are 
the best performers. 
 
Figure 65 – Pharmaceutical firms on Twitter: Engagement rate period 2 
 
 
Afterwards, a total engagement analysis (period 1 + period 2) was performed 
adopting the same approach used for each single period. As presented in Figure 66, there 
is not a direct relationship between engagement and the socioeconomic data. Like the 
period 2 analysis, the same two companies seem to outperform when comparing to the 
others. However, Teva continues to have the widest engagement diameter. 
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Figure 66 – Pharmaceutical firms on Twitter: Total engagement 
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4.2.1. Twitter cluster analysis 
A cluster analysis was performed in order to identify each cluster on Twitter. 
When analysing pharmaceutical companies’ presence on Twitter, five clusters were 
identified. Their composition is illustrated in Figure 67. Again, like in Facebook cluster 
analysis, the criteria for the cluster formation were the engagement data and the number 
of Followers (instead of the number of Fans) (see Annex VI). 
 
Figure 67 – Twitter cluster analysis 
 
 
In order to give designations to each Twitter cluster, a “Crosstabs” analysis was 
performed, using the two variables used in their definition (see Annex VII). According to 
Figure 68, the names assigned to each cluster are “Follower Lovers with Very Low to 
Medium Activity”, “Follower Friendly with Low to High Activity”, Weakly Active 
Follower Appreciators”, “Follower “Dislikers” with Very Low to Medium Activity” and 
“Follower Haters with High to Very High Activity”.  
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Figure 68 – Twitter cluster analysis with defined cluster names 
 
 
Each of the five clusters identified and named were subjected to a more detailed 
analysis in order to characterize them (see Annex IX). According to Table 13, each cluster 
appears to have singularities regarding each variable. The clusters have different 
intensities, as they are composed with companies with distinct behaviour. 
 
Table 13 – Twitter clusters: characterization 
 
Follower Lovers 
with Very Low to 
Medium Activity 
Follower Friendly 
with Medium 
Activity 
Weakly Active 
Follower Appreciators 
Follower 
“Dislikers” with 
Very Low to 
Medium Activity 
Follower Haters 
with High to Very 
High Activity 
Revenue +++ ++/-- + +/-- -- 
Employees +++/- ++/- ++/- +/--- -- 
Tweets (Lifetime) ++/- +++/-- ++/- ++/-- +/--- 
Tweets (Periods) ++/- +++/-- +/-- +/- +/-- 
Retweets ++ +++/- +/-- -- +/--- 
Mentions with 
Replies ++ +++/- + -- -- 
Customer Service 
Responses -- +++/-- ++/- -- ++/-- 
Note: 
-> Each + sign reveals the positive intensity in each parameter while each – sign reveals the negative intensity in each parameter, because clusters 
are not homogeneous. 
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4.3. YouTube data analysis 
The analysis of pharmaceutical presence on YouTube revealed that 15 companies 
have a YouTube Channel. In Figure 69, all the 15 companies which have a YouTube 
account are represented. Again it is important to restate that for this analysis, the company 
Genentech (part of Group Roche) was included in the Roche analysis, because it is 
responsible for the most successful medicines of Group Roche. Also Bayer’s YouTube 
channel was not directly related to Bayer Healthcare, so the company’s symbol in Figure 
69 was only related to Bayer. 
 
Figure 69 – Pharmaceutical firms analysed on YouTube 
 
 
Subscribers 
 
The subscribers are an important part of the activity of YouTube channels because 
they receive notifications for each new video. For this reason, it is important to analyse 
this parameter.  
According to Figure 70, the number of subscribers for each company can vary 
between 68 and 9.866 subscribers. One remarkable standout in the subscribers’ analysis 
is the dominance of Johnson & Johnson, registering the highest number of subscribers 
while the second biggest company is Amgen with only 3.320 subscribers. Also six 
companies registered a number of subscribers inferior to 1.000. 
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Figure 70 – Pharmaceutical firms analysed on YouTube: Number of subscribers 
 
 
Videos and their views 
 
Videos are tools of choice to share information on YouTube channels. Through 
Figure 71, it is possible to analyse the video distribution in each YouTube channel. 
Johnson & Johnson takes the lead in this category with 679 videos, corresponding to 29% 
of the total number of registered. For the other YouTube channels the number of videos 
can vary between 264 and 3 videos. 
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Figure 71 – Pharmaceutical firms analysed on YouTube: Number of videos 
 
 
When analysing, through Figure 72, the number of views in each YouTube 
channel, clearly one company stands out from the others.  
Johnson & Johnson is the outperformer in this category with 10.204.972 views, 
resulting in 58% of total number of views registered. The other YouTube channels 
register views numbers between 10.017 and 1.585.289 views. However, when analysing 
views per each video the scenario changes dramatically. 
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Figure 72 – Pharmaceutical firms analysed on YouTube: Video views 
 
 
According to Figure 73, the number of views for each video is clearly more 
homogenous when comparing the data from Figure 72. The leading company is now 
Roche (Genentech) with 22.328 views per videos, followed by Johnson & Johnson with 
15.029, and a third YouTube channel emerges (Amgen) with 13.602. The other 
companies vary between 226 and 8.314 views per video. 
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Figure 73 – Pharmaceutical firms analysed on YouTube: Views per video 
 
 
To establish a relationship between the number of views, videos and subscribers, 
Figure 74 was produced. According to the displayed data, it seems that, in general the 
number of views increases in a form of clusters with the increase of subscribers and 
videos. 
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Figure 74 – Pharmaceutical firms analysed on YouTube: Video views per firm 
 
 
Another interesting analysis is to compare the number of views per video with the 
socioeconomic data of each company. According to Figure 75, there is not a proportional 
growth of video views with the increase of the company’s size. 
 
Figure 75 – Pharmaceutical firms analysed on YouTube: Views per video / 
Socioeconomic data 
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Engagement 
 
The engagement rate for YouTube channels was defined as: Views per 
video/Subscribers. According to Figure 76, the engagement rate seems to decrease with 
the increase of companies’ revenue and number of employees (without proportionality), 
but there is not a strong association between these variables. 
 
Figure 76 – Pharmaceutical firms analysed on YouTube: Engagement by firm 
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4.3.1. YouTube cluster analysis 
Pharmaceutical companies’ YouTube channels were also subjected to a cluster 
analysis identical to the ones performed for Facebook and Twitter. As presented in Figure 
77, four clusters were identified using the “Hierarchical Cluster Analysis” of SPSS 
software (Annex VI). 
 
Figure 77 – YouTube cluster analysis 
 
 
As made for Facebook pages and Twitter accounts, another analysis was 
performed with the objective of assigning designations to each cluster. With the crossing 
of the variables “Engagement “and “Number of Subscribers”, it was possible to designate 
names to each cluster (see Annex VII).  
The results are displayed in Figure 78. The names assigned were “Subscriber 
Friendly with Low to Medium Activity”, Subscriber Appreciators with Medium 
Activity”, “Subscriber Haters Mostly Highly Active” and Weakly Active Subscriber 
Lovers”. 
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Figure 78 – YouTube cluster analysis with defined cluster names 
 
 
In order to analyse in detail each cluster, another “Crosstabs” analysis was 
performed, using several variables (see Annex X). According to Table 14, the clusters 
have differentiated activity between them and are not homogeneous because they can 
have companies that perform well in a variable and companies that perform poorly in the 
same variable. 
 
Table 14 – YouTube clusters: characterization 
 
Subscriber Friendly with 
Low to Medium Activity 
Subscriber Appreciators 
with Medium Activity 
Subscriber haters Mostly 
Highly Active 
Weakly Active Subscriber 
Lovers 
 Revenue ++/-- ++/- +/-- +/- 
Employees ++/- +++/- +/-- ++ 
Videos ++ +/- +/--- +++ 
Total Views +/- ++/- +/--- +++ 
Total Views / Videos +/-- +++/- +/-- ++ 
Note: 
-> Each + sign reveals the positive intensity in each parameter while each – sign reveals the negative intensity in each parameter, because clusters 
are not homogeneous. 
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4.4. Selected social media overview 
In this section, the three assessed social media platforms are subjected to an 
integrated analysis. The first important analysis is the evolution of pharmaceutical 
companies’ social media presence. In Table 15, there is a description of the social media 
platforms used by selected pharmaceutical companies in 2011 and 2014. The data of 2011 
were provided by Shankar and Li (2014) while the 2014 data were retrieved during this 
research.  
 
Table 15 – Evolution of pharmaceutical companies’ presence on Facebook, Twitter and 
YouTube 
Company 
Revenue 
2010(a) 
(million) 
Revenue 
2012(b) 
(million) 
2011(a) 2014 
      
Pfizer $58.523 $47.404 Yes Yes Yes Yes Yes Yes 
Novartis $44.420 $45.418 Yes Yes Yes Yes Yes Yes 
Merck & Co. $39.811 $41.143 Yes Yes Yes Yes Yes Yes 
Sanofi $37.403 $38.370 Yes Yes  Yes Yes(c) Yes  Yes 
GlaxoSmithKline $36.156 $33.107 Yes Yes Yes Yes Yes Yes 
AstraZeneca $32.515 $27.064 Yes Yes Yes Yes(c) Yes Yes 
Johnson & Johnson $22.396 $23.491 Yes Yes Yes Yes Yes Yes 
Eli Lilly & Co. $21.685 $18.509 Yes Yes Yes Yes Yes Yes 
Abbott Laboratories $19.984 $23.199 Yes Yes Yes Yes(e) Yes Yes(e) 
Bristol-Myers Squibb $19.484 $13.155 No Yes Yes No Yes No 
Teva $16.121 $17.681 Yes Yes Yes Yes Yes(d) No 
Takeda Pharma $14.829 $15.173 No Yes No No No No 
Bayer Schering $14.485 $14.734 Yes Yes Yes Yes Yes Yes 
Boehringer-Ingelheim $12.883 $13.686 Yes Yes Yes Yes Yes Yes 
Astellas $11.161 $10.835 Yes Yes Yes No Yes(c) Yes(c) 
Daiichi-Sankyo $10.794 $11.019 No Yes Yes No No No 
Gilead Sciences $7.390 $9.398 No Yes Yes No Yes No 
Note: 
(a) Top 20 pharmaceutical companies based on 2010 revenues and their social media presence. Source: Table 6 
(b) Raking and 2012 revenues based on Pharmaceutical Executive’s 50 top pharmaceutical companies 
(http://www.imsconsultinggroup.com/deployedfiles/consulting/Global/Content/How%20We%20Help/Strategy%20&%20Portfolio/PharmExec-
pharma50.pdf) 
(c) Social media platforms dedicated to USA population 
(d) Twitter account dedicated to Spanish population 
(e) Facebook page dedicated to jobs (Careers) while YouTube channel is dedicated to interns enrolled on an internship 
 
 
The data displayed in the table above shows that larger pharmaceutical companies 
did not change their presence, but the companies below Eli Lilly & Co reveal that they 
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are abandoning some social media platforms. The Japanese companies Takeda and 
Daiichi-Sankyo have abandoned completely the three assessed platforms while Astellas 
is not in the same situation because Astellas USA possesses a Twitter account and a 
YouTube channel. YouTube appears to be the most abandoned social media platform. 
An integrated analysis of digital engagement was also performed. Through Table 
16 it is possible to verify the different levels of engagement in each of the three social 
media platforms analysed. According to the displayed data, the two best performing 
companies on Facebook are Boehringer Ingelheim and Eli Lilly while on Twitter the first 
place is taken by Teva and in second place continues Eli Lilly. On YouTube two different 
companies (Abbott and Astellas) are in the top 2. 
 
Table 16 – Ranking of digital engagement on Facebook, Twitter and YouTube 
Ranking  Score                                         Score  Score 
1 Boehringer Ingelheim 0,078 Teva 18,170 Abbott 49,103 
2 Eli Lilly 0,074 Eli Lilly 9,971 Astellas Pharma 17,842 
3 Roche 0,041 Merck & Co. 4,840 Bayer 10,905 
4 Merck & Co. 0,038 Roche (Genentech) 4,238 Novo Nordisk 9,352 
5 Roche (Genentech) 0,038 Johnson & Johnson 3,252 Roche (Genentech) 7,699 
6 Teva 0,025 Novo Nordisk 2,425 Amgen 4,097 
7 Sanofi 0,015 Boehringer Ingelheim 2,122 Pfizer 2,880 
8 Novartis 0,015 Gilead Sciences 1,782 AstraZeneca 2,595 
9 GlaxoSmithKline 0,013 Bristol-Myers Squibb 1,603 Sanofi 2,163 
10 Novo Nordisk 0,009 Astellas Pharma 1,257 Boehringer Ingelheim 2,088 
11 Pfizer 0,007 Novartis 1,253 Eli Lilly 2,039 
12 Abbott 0,007 GlaxoSmithKline 1,130 Johnson & Johnson 1,523 
13 Bayer 0,006 Abbott 0,984 GlaxoSmithKline 1,437 
14 AstraZeneca 0,005 Roche 0,830 Merck & Co. 1,138 
15 
 
AstraZeneca 0,824 Novartis 1,033 
16 Bayer 0,817 Roche 0,917 
17 Sanofi 0,730 
 
18 Pfizer 0,728 
19 Amgen 0,640 
20  
 
In order to associate the level of engagement with the revenue of pharmaceutical 
companies, Table 17 was produced. It shows that smaller companies in terms of revenue 
seem to perform better, but there is no clear association between the amount of revenue 
and the level of engagement in the three platforms. It is also clear that the level of 
117 
 
engagement does not increase with the increase of revenue (this conclusion was also taken 
in the previous individual graphical representation of engagement for each platform). 
 
Table 17 – Ranking of digital engagement by revenue on Facebook, Twitter and 
YouTube 
Ranking 
Engagement 
 
Raking 
Revenue(a) 
(2012) 
                                        
Raking 
Revenue(a) 
(2012) 
 
Raking 
Revenue(a) 
(2012) 
1 Boehringer Ingelheim 15 Teva 11 Abbott 9 
2 Eli Lilly 10 Eli Lilly 10 Astellas Pharma 19 
3 Roche 5 Merck & Co. 3 Bayer 14 
4 Merck & Co. 3 Roche (Genentech) 5 Novo Nordisk 16 
5 Roche (Genentech) 5 Johnson & Johnson 8 Roche (Genentech) 5 
6 Teva 11 Novo Nordisk 16 Amgen 12 
7 Sanofi 4 Boehringer Ingelheim 15 Pfizer 1 
8 Novartis 2 Gilead Sciences 20 AstraZeneca 7 
9 GlaxoSmithKline 6 Bristol-Myers Squibb 17 Sanofi 4 
10 Novo Nordisk 16 Astellas Pharma 19 Boehringer Ingelheim 15 
11 Pfizer 1 Novartis 2 Eli Lilly 10 
12 Abbott 9 GlaxoSmithKline 6 Johnson & Johnson 8 
13 Bayer 14 Abbott 9 GlaxoSmithKline 6 
14 AstraZeneca 7 Roche 5 Merck & Co. 3 
15 
 
AstraZeneca 7 Novartis 2 
16 Bayer 14 Roche 5 
17 Sanofi 4 
 
18 Pfizer 1 
19 Amgen 12 
20  
Note: 
(a) Raking and 2012 revenues based on Pharmaceutical Executive’s 50 top pharmaceutical companies 
(http://www.imsconsultinggroup.com/deployedfiles/consulting/Global/Content/How%20We%20Help/Strategy%20&%20Portfolio/PharmExec-
pharma50.pdf) 
 
When analysing the level of engagement with the number of employees, the same 
conclusions of Table 17 were taken. According to Table 18, there is no association 
between the number of employees and the level of engagement. Therefore, the level of 
engagement does not increase with the increase of the workforce (again, the same 
conclusion was also taken in the previous individual graphical representation of 
engagement for each platform). 
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Table 18 – Ranking of digital engagement by employees on Facebook, Twitter and 
YouTube 
Ranking 
Engagement 
 Raking 
Employees(a) 
                                        Raking 
Employees(a) 
 Raking 
Employees(a) 
1 Boehringer Ingelheim 11 Teva 12 Abbott 8 
2 Eli Lilly 14 Eli Lilly 14 Astellas Pharma 19 
3 Roche 5 Merck & Co. 7 Bayer 9 
4 Merck & Co. 7 Roche (Genentech) 5 Novo Nordisk 13 
5 Roche (Genentech) 5 Johnson & Johnson 2 Roche (Genentech) 5 
6 Teva 12 Novo Nordisk 13 Amgen 18 
7 Sanofi 3 Boehringer Ingelheim 11 Pfizer 6 
8 Novartis 1 Gilead Sciences 20 AstraZeneca 7 
9 GlaxoSmithKline 4 Bristol-Myers Squibb 17 Sanofi 3 
10 Novo Nordisk 13 Astellas Pharma 19 Boehringer Ingelheim 11 
11 Pfizer 6 Novartis 1 Eli Lilly 14 
12 Abbott 8 GlaxoSmithKline 4 Johnson & Johnson 2 
13 Bayer 9 Abbott 8 GlaxoSmithKline 4 
14 AstraZeneca 10 Roche 5 Merck & Co. 7 
15 
 
AstraZeneca 10 Novartis 1 
16 Bayer 9 Roche 5 
17 Sanofi 3 
 
18 Pfizer 1 
19 Amgen 12 
20  
Note: 
(a) For further detail see Annex V (Table 23) 
 
Another important observation is the fact that it seems that each company does 
not share the same digital engagement strategy (see Figure 79). Through the cluster 
analysis, companies were assigned to different clusters in each platform.  
However, it seems that Eli Lilly shares some similarities between Facebook and 
Twitter digital engagement strategy. Using Table 16, the same scenario is observed. Firms 
do not achieve the same engagement raking in all the social media platforms under 
analysis. 
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Figure 79 – Overview of the digital strategy on Facebook, Twitter and YouTube 
 
From all of the above statistical results, we can infer that social media strategy 
differs in this group of pharmaceutical firms, resulting in different engagements levels in 
Facebook, Twitter and YouTube.  
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CHAPTER 5 – FINAL CONSIDERATIONS 
 
In the last 10 years, social media took over the online world, connecting more 
people, firms and brands. However, there are a number of industries that are still lacking 
in social media exposure and interaction with costumers. The question that remains 
unanswered is what leads to a greater firms’ investment in social media and in which 
media?   
In the pharmaceutical industry, social media is a tool that is in fact used to 
communicate with consumers. However, not all pharmaceutical companies have a 
Facebook page, Twitter account or YouTube channel. In fact, only a reduced number of 
the pharmaceutical companies analysed is in the three social media platforms 
simultaneously. Also it seems that smaller pharmaceutical companies are leaving some 
social media platforms. These observations could be a result of an absence of official 
guidance in the use of such platforms associated with difficulty to calculate return on 
investment in the same platforms. 
The analysis of the activity of pharmaceutical companies on social media revealed 
that in the several parameters studied for each social media platform there were diverse 
settings of scenarios, with some companies performing better than others in one 
parameter but with a poor performance in others. Also some companies appeared almost 
non-active in such platforms. Moreover, when analysing the ultimate indicator of activity 
(engagement raking), smaller companies leaded the raking. However, there is not an 
association between a good performance in this raking with the size of the companies in 
terms of revenue and employees. This suggests that other factors could influence digital 
engagement, and therefore they should be evaluated in future researches. Regarding their 
digital engagement strategy, pharmaceutical companies do not use the same strategy 
between the three social media platforms analysed. The clusters analysis showed that in 
general pharmaceutical companies behave differently in Facebook, Twitter and YouTube, 
as they were distributed to clusters/segments, presenting different characteristics among 
these platforms.  
Social media in the pharmaceutical environment is clearly taking the first steps. 
This is leading to an increase of researchers’ curiosity and work in this field. However, 
the number of publications regarding this thematic is small and it does not provide, in 
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detail, the elements composing the activity of pharmaceutical companies on social media. 
The only study which refers to a detailed classification of this activity is a non-published 
article of 2014 from a private institution. 
Therefore, the research developed in this document provides a comprehensive 
overview of pharmaceutical marketing communication strategies and enhances the 
knowledge regarding communication through social media in this specific sector. In this 
way, it offers a literature review up-to-date which can deliver valuable insights to other 
researchers.  
Another valuable contribution of this research is the fact that it provides an 
innovative conceptual model and methodology that can be replicated in future studies. 
The analysis of the social media activity of pharmaceutical companies on Facebook, 
Twitter and YouTube provides a first separated and detailed evaluation of how these 
companies behave on social media. With this analysis, the literature will benefit of an 
extensive overview of the topic of this research, while the firm’s management can see if 
their companies are having an outstanding performance when comparing to their 
competitors. 
When developing a research in an emergent domain in society, several limitations 
can arise because the literature does not provide full support regarding several essential 
elements, such as a robust methodology, previously tested by other fellow researchers. In 
this way, the methodology developed in this research presents several limitations related 
to its innovative nature, but it also represents a path for future researches. 
The methodology adopted in this research allows identifying the social media 
websites of the selected pharmaceutical companies. However, its process does not 
guarantee that all the websites are related to healthcare and if so some can be classified 
as official websites and others unofficial (because of the absence of social media 
indication in the company’s main website). In order to avoid possible mistakes in this 
field, future researchers must contact the enterprises involved in the study to make sure 
which are the official social media websites. Also the inclusion of Genentech in Roche 
analysis can be deceiving as the first one has its own activity (revenue and employees). 
Consequently, future researchers must take extra caution when evaluating this type of 
inclusions. Furthermore, in the methodology used, only the 20 top pharmaceutical 
companies were analysed. However, to have a bigger understanding of the situation of 
the social media used by pharmaceutical companies, future researchers must try to analyse 
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a larger sample of companies, and therefore transforming their research into one that can 
be extrapolated to the reality of the pharmaceutical industry. 
The data gathering for this research also presents limitations. These data were 
collected resorting to private companies which have tools that can retrieve data from 
social media websites. However, the data retrieved in Facebook and Twitter have some 
limitations because these tools are for free. Simplymeasured.com tools for Facebook only 
allow data from a period of two weeks and social media websites with more than 250.000 
likes cannot be analysed (Johnson & Johnson’s Facebook page was not analysed due to 
this last restriction). For Twitter, only a period of seven days can be analysed each time 
and customer service analysis is limited to 100.000 followers. To have a robust analysis 
that can clearly represent the reality of social media situation for pharmaceutical 
companies, future researchers must choose gathering methods that offer no limitations, 
as it is the paid Simplymeasuared.com tools. 
The multi-faced communication in the virtual world has recognized consequences 
besides its connectivity benefits. Pharmaceutical firms are challenged to adopt an 
increasing digital presence, following social media major trends. Therefore, this work is 
a small step towards the knowledge of the full potential of social media to this sector and 
it leaves clues to future researches. 
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Annex I – Research of pharmaceutical companies’ social media 
Table 19 – Research of pharmaceutical companies’ social media 
Ranking(a) Company Revenue
(a) 
(million) Website address 
Facebook 
reference on 
the website 
Twitter 
reference on 
the website 
YouTube 
reference on 
the website 
1 Pfizer $47.404 www.pfizer.com Yes Yes Yes 
2 Novartis $45.418 www.novartis.com Yes Yes Yes 
3 Merck & Co. $41.143 www.merck.com Yes Yes Yes 
4 Sanofi $38.370 www.sanofi.com(b) No Yes Yes 
5 Roche $37.542 www.roche.com Yes Yes Yes 
6 GlaxoSmithKline $33.107 www.gsk.com Yes Yes Yes 
7 AstraZeneca $27.064 www.astrazeneca.com(c) No Yes Yes 
8 Johnson & Johnson $23.491 www.jnj.com Yes Yes Yes 
9 Abbott Laboratories $23.119 www.abbott.com Yes Yes Yes 
10 Eli Lilly $18.509 www.lilly.com Yes Yes Yes 
11 TEVA $17.681 www.tevapharm.com(d) Yes No No 
12 Amgen $16.639 www.amgen.com No Yes Yes 
13 Takeda $15.173 www.takeda.com No No No 
14 Bayer $14.734 www.healthcare.bayer.com(e) Yes No No 
15 Boehringer Ingelheim $13.686 www.boehringer-ingelheim.com Yes Yes Yes 
16 Novo Nordisk $13.478 www.novonordisk.com Yes Yes Yes 
17 Bristol-Myers Squibb $13.155 www.bms.com No Yes No 
18 Daiichi-Sankyo $11.019 www.daiichisankyo.com No No No 
19 Astellas Pharma $10.835 www.astellas.com(f) No No No 
20 Gilead Sciences $9.398 www.gilead.com No Yes(g) No 
Note: 
(a) Raking and 2012 revenues based on Pharmaceutical Executive’s 50 top pharmaceutical companies 
(http://www.imsconsultinggroup.com/deployedfiles/consulting/Global/Content/How%20We%20Help/Strategy%20&%20Portfolio/PharmExec-
pharma50.pdf) 
(b) On www.sanofi.us, there is a reference for Sanofi US on Twitter and Facebook 
(c) On www.astrazeneca-us.com/about-us/social-media, there is a reference for AstraZeneca US on Twitter and Facebook 
(d) On www.tevagenericos.es there is a reference of a Twitter account that is dedicated to TEVA Spain 
(e) On www.bayer.com/en/socialmedia.aspx there is a list of the social media channels, but on the www.healthcare.bayer.com (the Bayer 
Healthcare division) there is only a reference of the Facebook page 
(f) On www. astellas.us there is a reference to Astellas Pharma US Twitter and YouTube account 
(g) http://www.gilead.com/twitter-guidelines 
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Annex II – Pharmaceutical companies’ Facebook pages links 
Table 20 – Pharmaceutical companies’ Facebook pages links 
Ranking(c) Company Revenue
(c) 
(million) 
 
1 Pfizer $47.404 https://www.facebook.com/Pfizer 
2 Novartis $45.418 https://www.facebook.com/novartis 
3 Merck & Co. $41.143 https://www.facebook.com/MerckBeWell 
4 Sanofi(a) $38.370 https://www.facebook.com/sanofiUS  
5 Roche(b) $37.542 https://www.facebook.com/RocheCareers (Facebook page dedicated to careers) https://www.facebook.com/Genentech (Part of Roche Group) 
6 GlaxoSmithKline $33.107 https://www.facebook.com/GSK 
7 AstraZeneca(a) $27.064 https://www.facebook.com/AstraZenecaUSCommunityConnections 
8 Johnson & Johnson $23.491 https://www.facebook.com/jnj 
9 Abbott $23.119 https://www.facebook.com/AbbottCareers (Facebook page dedicated to careers) 
10 Eli Lilly $18.509 https://www.facebook.com/elilillyandco 
11 Teva $17.681 https://www.facebook.com/tevapharm 
12 Amgen $16.639 - 
13 Takeda $15.173 - 
14 Bayer $14.734 https://www.facebook.com/healthcare.bayer 
15 Boehringer Ingelheim $13.686 https://www.facebook.com/boehringeringelheim 
16 Novo Nordisk $13.478 https://www.facebook.com/novonordisk 
17 Bristol-Myers Squibb $13.155 - 
18 Daiichi-Sankyo $11.019 - 
19 Astellas Pharma $10.835 - 
20 Gilead Sciences $9.398 - 
Note: 
(a) Facebook pages dedicated to USA population 
(b) Genentech was included because it is part of Group Roche, and it is accountable for the most successful medicines of Group Roche 
(c) Raking and 2012 revenues based on Pharmaceutical Executive 50 Top Pharmaceutical companies 
(http://www.imsconsultinggroup.com/deployedfiles/consulting/Global/Content/How%20We%20Help/Strategy%20&%20Portfolio/PharmExec-
pharma50.pdf) 
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Annex III – Pharmaceutical companies’ Twitter accounts links 
Table 21 – Pharmaceutical companies’ Twitter accounts links 
Ranking(d) Company Revenue
(d) 
(million) 
 
1 Pfizer $47.404 https://twitter.com/pfizer 
2 Novartis $45.418 https://twitter.com/novartis 
3 Merck & Co. $41.143 https://twitter.com/merck 
4 Sanofi $38.370 https://twitter.com/sanofi 
5 Roche(a) $37.542 https://twitter.com/roche https://twitter.com/genentech (Part of Roche Group) 
6 GlaxoSmithKline $33.107 https://twitter.com/gsk 
7 AstraZeneca $27.064 https://twitter.com/astrazeneca 
8 Johnson & Johnson $23.491 https://twitter.com/JNJCares 
9 Abbott $23.119 https://twitter.com/AbbottNews 
10 Eli Lilly $18.509 https://twitter.com/EliLillyCo 
11 Teva(b) $17.681 https://twitter.com/teva_es 
12 Amgen $16.639 https://twitter.com/amgen 
13 Takeda $15.173 - 
14 Bayer $14.734 https://twitter.com/BayerHealthCare 
15 Boehringer Ingelheim $13.686 https://twitter.com/boehringer 
16 Novo Nordisk $13.478 https://twitter.com/novonordisk 
17 Bristol-Myers Squibb $13.155 https://twitter.com/BMSNEWS 
18 Daiichi-Sankyo $11.019 - 
19 Astellas Pharma(c) $10.835 https://twitter.com/astellasus  
20 Gilead Sciences $9.398 https://twitter.com/GileadSciences 
Note: 
(a) Genentech was included because it is part of Group Roche, and it is accountable for the most successful  medicines of Group Roche 
(b) Twitter account dedicated to Spanish population 
(c) Twitter account dedicated to USA population 
(d) Raking and 2012 revenues based on Pharmaceutical Executive 50 Top Pharmaceutical companies 
(http://www.imsconsultinggroup.com/deployedfiles/consulting/Global/Content/How%20We%20Help/Strategy%20&%20Portfolio/PharmExec-
pharma50.pdf 
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Annex IV – Pharmaceutical companies’ YouTube channels links 
Table 22 – Pharmaceutical companies’ YouTube channels links 
Ranking(c) Company Revenue
(c) 
(million)  
1 Pfizer $47.404 https://www.youtube.com/user/Pfizernews 
2 Novartis $45.418 http://www.youtube.com/user/Novartis/ 
3 Merck & Co. $41.143 http://www.youtube.com/user/Merck 
4 Sanofi $38.370 http://www.youtube.com/user/sanofiaventisTVen/ 
5 Roche(a) $37.542 http://www.youtube.com/user/roche  https://www.youtube.com/user/Genentech (Part of Roche Group) 
6 GlaxoSmithKline $33.107 http://www.youtube.com/user/GSKvision 
7 AstraZeneca $27.064 http://www.youtube.com/user/astrazeneca 
8 Johnson & Johnson $23.491 http://www.youtube.com/user/JNJhealth 
9 Abbott $23.119 http://www.youtube.com/user/abbottinternship (Dedicated to Interns) 
10 Eli Lilly $18.509 http://www.youtube.com/user/EliLillyandCompany 
11 Teva $17.681 - 
12 Amgen $16.639 http://www.youtube.com/user/Amgen 
13 Takeda $15.173 - 
14 Bayer $14.734 https://www.youtube.com/user/BayerGroup  
15 Boehringer Ingelheim $13.686 http://www.youtube.com/user/boehringeringelheim 
16 Novo Nordisk $13.478 http://www.youtube.com/user/novonordisk 
17 Bristol-Myers Squibb $13.155 - 
18 Daiichi-Sankyo $11.019 - 
19 Astellas Pharma(b) $10.835 http://www.youtube.com/user/AstellasUS 
20 Gilead Sciences $9.398 - 
Note: 
(a) Genentech was included because it is part of Group Roche, and it is accountable for the most successful  medicines of Group Roche 
(b) YouTube channel dedicated to USA population 
(c) Raking and 2012 revenues based on Pharmaceutical Executive 50 Top Pharmaceutical companies 
(http://www.imsconsultinggroup.com/deployedfiles/consulting/Global/Content/How%20We%20Help/Strategy%20&%20Portfolio/PharmExec-
pharma50.pdf 
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Annex V – Pharmaceutical companies’ employees 
Table 23 – Pharmaceutical companies’ employees 
Ranking(a) Company Revenue
(a) 
(million) Website address Employees
(b) 
1 Pfizer $47.404 www.pfizer.com 78.000 
2 Novartis $45.418 www.novartis.com 135.696 
3 Merck & Co. $41.143 www.merck.com 76.000 
4 Sanofi $38.370 www.sanofi.com 112.128 
5 Roche $37.542 www.roche.com 85.080 
6 GlaxoSmithKline $33.107 www.gsk.com 99.451 
7 AstraZeneca $27.064 www.astrazeneca.com 51.500 
8 Johnson & Johnson $23.491 www.jnj.com 128.100 
9 Abbott Laboratories $23.119 www.abbott.com 69.000 
10 Eli Lilly $18.509 www.lilly.com 38.000 
11 TEVA $17.681 www.tevapharm.com 46.400 
12 Amgen $16.639 www.amgen.com 20.000 
13 Takeda $15.173 www.takeda.com 31.225 
14 Bayer $14.734 www.bayer.com 56.000 
15 Boehringer Ingelheim $13.686 www.boehringer-ingelheim.com 47.400 
16 Novo Nordisk $13.478 www.novonordisk.com 40.000 
17 Bristol-Myers Squibb $13.155 www.bms.com 24.000 
18 Daiichi-Sankyo $11.019 www.daiichisankyo.com 30.000 
19 Astellas Pharma $10.835 www.astellas.com 17.649 
20 Gilead Sciences $9.398 www.gilead.com 6.400 
Note: 
(a) Raking and 2012 revenues based on Pharmaceutical Executive 50 Top Pharmaceutical companies 
(http://www.imsconsultinggroup.com/deployedfiles/consulting/Global/Content/How%20We%20Help/Strategy%20&%20Portfolio/PharmExec-
pharma50.pdf) 
(b) Number of employees retrieved from company’s website, annual report or from the Wikipedia website 
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Annex VI – Hierarchical Cluster Analysis 
 
Figure 80 – Facebook Hierarchical Cluster Analysis 
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Figure 81 – Twitter Hierarchical Cluster Analysis 
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Figure 82 – YouTube Hierarchical Cluster Analysis 
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Annex VII – Crosstabs Cluster Analysis (bivariate) 
 
Figure 83 – Facebook Crosstabs Cluster Analysis  (Fans and Engagement) 
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Figure 84 – Twitter Crosstabs Cluster Analysis  (Followers and Engagement) 
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Figure 85 – YouTube Crosstabs Cluster Analysis  (Subscribers and Engagement)  
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Annex VIII – Facebook Crosstabs Cluster Analysis (multivariate) 
 
Figure 86 – Facebook Crosstabs Cluster Analysis (Case Processing Summary) 
 
 
 
 
 
Figure 87 – Facebook Crosstabs Cluster Analysis (Revenue) 
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Figure 88 – Facebook Crosstabs Cluster Analysis (Employees and Brand posts) 
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Figure 89 – Facebook Crosstabs Cluster Analysis (Shares of Brand posts and Likes of 
Brand posts) 
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Figure 90 – Facebook Crosstabs Cluster Analysis (Comments of brand posts and User 
posts) 
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Annex IX – Twitter Crosstabs Cluster Analysis (multivariate) 
 
Figure 91 – Twitter Crosstabs Cluster Analysis (Case Processing Summary) 
 
 
 
 
 
 
 
 
 
 
Figure 92 – Twitter Crosstabs Cluster Analysis (Revenue) 
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Figure 93 – Twitter Crosstabs Cluster Analysis (Employees and Tweets (Lifetime))  
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Figure 94 – Twitter Crosstabs Cluster Analysis (Tweets (Periods) and Retweets) 
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Figure 95 – Twitter Crosstabs Cluster Analysis (Mentions with replies and Customer 
Service Responses) 
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Annex X – YouTube Crosstabs Cluster Analysis (multivariate) 
 
Figure 96 – YouTube Crosstabs Cluster Analysis (Case Processing Summary) 
 
 
 
 
 
 
Figure 97 – YouTube Crosstabs Cluster Analysis (Case Processing Summary) 
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Figure 98 – YouTube Crosstabs Cluster Analysis (Employees and Total Views) 
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 Figure 99 – YouTube Crosstabs Cluster Analysis (Videos and Views per Video)  
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